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Abstract 
The peroxidase activity of the mitochondrial protein cytochrome c (cyt c) plays a 
critical role in triggering programmed cell death, or apoptosis. However, the native 
structure of cyt c should render this activity impossible due to the lack of open iron 
coordination sites at its heme cofactor. Despite its key biological importance, the molecular 
mechanisms underlying this structure-function mismatch remain enigmatic. The work 
detailed in this dissertation fills this knowledge gap by using mass spectrometry (MS) to 
decipher the central role that protein oxidative modifications and their associated structural 
changes play in activating the peroxidase function of cyt c. 
 
Chapter 2 uses a suite of MS-based experiments to identify and characterize 
oxidative modifications in cyt c caused by the oxidant and canonical peroxidase substrate, 
H2O2. In doing so, we unravel the critical role that these in situ structural changes play in 
triggering the peroxidase activity of the protein via alteration of the coordination 
environment. Serendipitously, we also discover that certain functionally important 
oxidative modifications, particularly on Lys, can elude detection when using conventional 
bottom-up MS approaches. However, by applying top-down MS we could successfully 
detect these modifications. 
 
Chapter 3 re-examines a popular and purportedly well-characterized model system 
for peroxidase-activated cyt c: cyt c treated with chloramine-T. By combining top-down 
MS with sample fractionation techniques, we uncover that this model system is in fact 
comprised of a broad ensemble of structurally and functionally distinct species. These 
species can be differentiated by the extent of oxidation at key Lys residues, which 
previously went undetected. 
 
Chapter 4 expands on the previous chapters by probing the causal factors 
underpinning the production of oxidative modification products at Lys and other residues. 
We discover that Lys oxidation is catalyzed by the endogenous heme cofactor, while other 
transformations (e.g. Met oxidation) proceed via direct interaction with the oxidant. 
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Chapter 5 utilizes oxidized cyt c as a model system to test the compatibility of 
protein stability measurements in the gas phase to their counterparts in solution. Unlike 
many other protein systems, we discover that oxidized cyt c shows opposing stability trends 
in solution and in the gas phase. 
 
 
 
 
Keywords: mass spectrometry, cytochrome c, peroxidase, protein oxidation, oxidative 
damage, ion mobility spectrometry.  
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Summary for Lay Audience 
Proteins are large molecules comprised of amino acids that play important roles in 
many aspects of biology. Proteins adapt a variety of functions, depending on their structure. 
Cytochrome c (cyt c) is a protein found in the mitochondria of cells that normally functions 
as an electron transporter, which is possible because of the iron-containing heme group in 
cyt c. Cyt c also has an alternative function (as a peroxidase), which plays a key role in 
triggering programmed cell death, or apoptosis. Despite this importance, it is poorly 
understood how cyt c can have peroxidase function despite structural features that should 
render it inactive. In this dissertation, we use mass spectrometry (MS) to study how 
oxidants can interact with cyt c, altering its structure and accommodating its peroxidase 
function. 
 
We first studied the effects of the oxidant hydrogen peroxide (H2O2) on the 
structure and function of cyt c (Chapter 2). We uncovered that cyt c is extensively modified 
by H2O2. Using MS, we determined that these oxidative modifications cause structural 
changes near the heme that enable peroxidase function. A key finding was that oxidation 
of one type of amino acid, lysine, was critical. 
 
We next focused on another oxidant, chloramine-T (CT) (Chapter 3). CT-treated 
cyt c has long been a popular model system for studying apoptosis and is thought to be 
simple and well-characterized. Using a combination of MS and purification techniques, we 
discovered that CT-treated cyt c is actually a mixture of structurally and functionally 
distinct species. The main difference between these species was the presence of lysine 
oxidation at key positions on the protein. 
 
We then explored the processes underlying the formation of oxidative 
modifications in cyt c (Chapter 4). We determined that the heme plays a key role in 
producing lysine oxidation, while other amino acids (e.g. methionine) were oxidized 
independently of the heme group. 
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Finally, we used oxidized cyt c to compare the differences in protein stability using 
MS versus conventional spectroscopic techniques in solution (Chapter 5). Unlike many 
other proteins, we found that oxidized cyt c showed opposing stability trends in these two 
types of measurements.  
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Chapter 1. Introduction 
 
 
1.1. Protein Structure and Function 
Proteins are biological macromolecules composed of a linear polymer of α-amino 
acids. These building blocks are linked via amide bonds between the amine and carboxylate 
groups of consecutive residues (Figure 1-1). Each monomer can be one of 20 proteogenic 
amino acids, which differ by their side chain moiety.  
 
Proteins are involved in virtually every aspect of biological function.1 This 
enormous versatility is possible due to the vast multitude of possible three-dimensional 
structures that can arise from a polypeptide chain. A hallmark of proteins is their propensity 
to fold into highly ordered structures; the overall conformation is determined by their 
sequence, as well as the chemical environment surrounding the protein (pH, ionic strength, 
chemical modifications, etc.).2 Some proteins may also incorporate non-amino acid 
elements, known as co-factors. These co-factors can associate with the protein through 
noncovalent or covalent interactions. A central tenet of structural biology is that the 
function of a protein is dictated by its structure. 
 
 
 
  
Figure 1-1. Generic chemical structures of (A) α-amino acids and (B) polypeptides. 
Different sidechains, R, give rise to each of the different amino acid residues.  
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One phenomenon that is of growing interest is the ability of some proteins to 
perform multiple, sometimes radically different functions, often termed protein 
“moonlighting”.3,4 Typically, such proteins are known for a primary, canonical function, 
but have been found to also perform other, non-canonical functions. Some of this 
moonlighting is possible without an accompanying change in structure (e.g. when different 
functions are linked to different domains of the protein). Other cases require a change in 
conformation that may be triggered by an altered chemical environment (e.g. cellular 
location, pH, post-translational modifications, ligand-binding, etc.). 
 
 
1.2. Cytochrome c 
One protein that exhibits moonlighting functionality is cytochrome c (cyt c), a 
highly conserved,5 12 kDa heme-containing protein (or hemeprotein) normally found in 
the intermembrane space of mitochondria.6 The c-type heme cofactor of cyt c is covalently 
bound to the protein through thioether linkages to Cys14 and Cys17. In the native protein 
the iron center is hexa-coordinated, with four dative bonds from nitrogens in the porphyrin 
ring, one from the imidazole side chain of His18, and another from the thioether sulfur of 
Met80 (Figure 1-2). The canonical function of cyt c is to act as an electron carrier between 
complexes III and IV in the respiratory electron transport chain, cycling between the Fe(II) 
and Fe(III) oxidation states.7,8 However, cyt c also possesses a moonlighting function as a 
peroxidase.9–12 
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Figure 1-2. (A): Crystal structure of cyt c (equine, PDB: 1HRC)13; (B): Magnified view of 
the heme center; (C) Schematic representation of the heme center. 
 
Peroxidases are a class of hemeproteins that catalyze the oxidation of substrates 
using H2O2, with the most well-known example being horseradish peroxidase (HRP).14 In 
this capacity, cyt c was found to play a crucial role in apoptosis (programmed cell death) 
by catalyzing the peroxidation of membrane lipids (via formation of lipid radicals and 
subsequent non-enzymatic reaction with molecular oxygen).15 This process increases the 
permeability of the mitochondrial membrane and allows the passage of cyt c into the 
cytoplasm, where interactions between cyt c and apoptotic factors initiate apoptosis.16–20 
Although the precise mechanism is not fully understood, it is generally thought that cyt c 
exhibits peroxidase activity in a manner similar to that of other peroxidases by catalyzing 
the heterolytic cleavage of H2O2 via cycling between Fe(III) and Fe(IV) oxidation states 
(Figure 1-3).14 There is also some evidence that cyt c may also be able to catalyze homolytic 
H2O2 cleavage to directly produce hydroxyl radicals (∙OH).21,22 
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Figure 1-3. Functions of cyt c. (A) electron carrier function. (B) peroxidase function based 
on the mechanism for classical peroxidases.14 The porphyrin ring is represented here as a 
disc. The produced radical species may undergo further reactions with molecular oxygen 
to form various oxidized products.  
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Regardless of the mechanistic details, all proposed explanations of cyt c peroxidase 
activity require an Fe(III) species with an open distal coordinate site that can bind H2O2, in 
line with HRP and other peroxidases.14 In the native conformation of cyt c, this distal site 
is occupied by Met80 (Figure 1-2C). As such, numerous studies have explored how an 
assortment of protein-ligand interactions, post-translational modifications, and/or 
mutations can promote dissociation of the Met80-Fe bond, and how this may trigger the 
functional switch from an electron carrier to a peroxidase.10–12,23–29 Studies in vivo have 
shown that cyt c mutants lacking Met80 show increased peroxidase activity and promoted 
release of cyt c into the cytoplasm from the mitochondria.30 Other studies have shown that 
binding to anionic lipid molecules such as cardiolipin,31–33 as well as certain post-
translational modifications (e.g. Tyr74 nitration)34, result in changes of the coordination 
environment that are correlated with increased peroxidase activity. One of the most-studied 
alternate cyt c forms is the so-called “alkaline conformer”, where a lysine residue (likely 
Lys72/73) is the 6th ligand in place of Met80.35–37 Unexpectantly, the alkaline conformer 
exhibits enhanced peroxidase activity, despite also lacking an open coordination site to 
bind H2O2.26,38 
 
Despite decades of research studying the various effectors of the peroxidase activity 
of cyt c, a long-standing enigma is that cyt c, in its native state hexacoordinate state, is 
peroxidase-active.9 While there have been some attempts to address this paradox in both 
the native state and the alkaline conformer (e.g. partial pentacoordinate occupancy via 
conformational fluctuations)39,40, the phenomenon remains poorly understood. 
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1.3. Protein Oxidation 
Exposure of proteins and other biomolecules to reactive oxygen species (ROS) such 
as H2O2, ∙OH, and ∙O2- is an unavoidable consequence of aerobic cellular respiration.41,42 
ROS can induce covalent (oxidative) modifications, many of which have pronounced 
effects on protein structure and function. Accumulation of oxidized protein is correlated 
with disease states related to aging43–45 and neurodegeneration.46–52 Proteins at high risk of 
oxidation (e.g. redox-active metalloenzymes) are thought to have evolved protective 
mechanisms to mitigate these deleterious effects (e.g. controlled electron hole hopping).53–
55 Aside from their negative consequences, protein oxidative modifications also play 
important roles in cell signalling and in regulating the cellular response to oxidative 
stress.56–58 
 
A wide variety of protein oxidation products exist for almost every amino acid 
residue.59–62 The most common oxidation targets are the sulfur-containing (Cys, Met) and 
aromatic (Trp, Tyr, Phe) residues. Oxidation of these residues typically results in the 
incorporation of one or more oxygen atoms, producing a series of +nO modifications.61,62 
The residues Cys and Tyr can also oxidatively dimerize to form cystine63 and dityrosine64,65, 
respectively. Mass spectrometry is commonly used to detect these oxidative modifications 
due to their characteristic changes in mass.61,62 
 
Another class of protein oxidative modifications are carbonylation products, in 
which a reactive carbonyl (i.e. ketone or aldehyde) is produced.46,62 These types of 
modifications are often studied by applying spectroscopic and/or antibody-based 
quantitative assays that utilize the reactivity these moieties with 2,4-
dinitrophenylhydrazine (DNPH) or other hydrazines.66,67 Glu and Lys are the most 
common targets of protein carbonylation,68 although carbonylation at other residues are 
also known.62 
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1.4. Common Methods for Studying Protein Structure 
1.4.1. Optical Spectroscopy 
Optical spectroscopy utilizes the interactions between photons and chemical matter 
to glean information on various physical and chemical properties of a system.69 In the 
context of studying protein structure, two common optical techniques are circular 
dichroism (CD) spectroscopy and fluorescence spectroscopy. 
 
CD spectroscopy takes advantage of the chirality of proteins and their constituent 
L-amino acids.70 When interacting with circularly polarized light (which can be either left- 
or right-handed) chiral molecules will absorb each of these two components to a different 
degree. The difference between these two absorbances produces the CD signal. For proteins, 
far-UV photons (ca. 190 – 250 nm) are typically used, corresponding to π → π* and n → 
π* electronic transitions of backbone amide groups.71 As the CD transitions are sensitive 
to the three-dimensional arrangement of the polypeptide backbone,72 each type of 
secondary structure (e.g. α-helix, β-sheet) gives rise to characteristic CD signals. The 
secondary structure content of a protein can be estimated by fitting experimental CD 
spectra to a linear combination of the “pure” basis spectra.73 Due to its convenience and 
sensitivity to changes in secondary structure, CD spectroscopy is often used in protein 
folding studies.74 Protein unfolding curves can be generated by plotting CD signals at a 
given wavelength as a function of temperature or denaturant concentration.75 Various 
thermodynamic parameters can be extracted from these experiments.76 
 
Fluorescence spectroscopy utilizes the capacity for some chromophores to emit 
light (fluoresce) following irradiation. Fluorescence spectroscopy offers the advantages of 
high sensitivity and low background intensity, thereby providing very high S/N ratios.77 
For protein studies, the fluorescence of intrinsic tryptophan residues is commonly 
utilized.78,79 Upon irradiation at 280 nm, these residues fluoresce at ca. 350 nm. Both the 
intensity and wavelength of the emission are a sensitive probe for the tryptophan 
microenvironment.79 Polar environments (e.g. solvent exposure) induce a red shift in the 
emission wavelength, whereas hydrophobic environments (e.g. the protein core) induce a 
blue shift. Fluorescence quenching can also be used to provide proximity information.80 
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UV/vis spectroscopy of most proteins does not provide much structural information. 
However, the heme cofactor is itself a chromophore that absorbs strongly in the visible 
range, enabling several optical analyses unique to hemeproteins in this range of the 
electromagnetic spectrum.81 The positions and relative intensities of the heme absorption 
bands (e.g. the Soret band at ca. 400 nm and the Q band at ca. 550 nm) are affected by 
changes in ligation state of the heme iron.82 This strong absorbance also renders the use of 
resonance Raman (RR) spectroscopy viable.83 RR spectroscopy is a variant of Raman 
spectroscopy that exploits the ability of highly absorbing electronic transitions to greatly 
enhance the intensity of Raman scattering. Raman spectroscopy probes the vibronic 
structure of system, and thereby provides insight into the environment surrounding the 
heme iron.84 
 
 
1.4.2. High-Resolution Structural Techniques 
A number of biophysical techniques allow the determination of protein structures 
with atomic (or near-atomic) resolution. Nuclear magnetic resonance (NMR) spectroscopy 
provides structural information from direct solution phase measurements, whereas X-ray 
diffraction (XRD) and cryo-electron microscopy (cryo-EM) obtain structure from 
measurements in the solid-state. 
 
NMR spectroscopy utilizes nuclear spin transitions to obtain chemical information 
on a molecule.85 Samples are placed in a strong external magnetic field, which causes the 
nuclear spin states to become non-degenerate (the Zeeman effect). A series of radio 
frequency (RF) pulses can then be applied to excite the nuclear spins. The energies of these 
transitions (usually reported as chemical shifts) are sensitive to the chemical environment 
of each nucleus. Typical NMR spectroscopy workflows for protein structure determination 
employ a series of multi-dimensional experiments that together first establish atomic 
connectivity.85–87 Afterwards, Nuclear Overhauser Effect Spectroscopy (NOESY) 
experiments are performed that provide distance constraints between various nuclei.88–90 
By combining these constraints with chemical shift information, model protein structures 
can be built using molecular mechanics force fields.91,92 Protein NMR spectroscopy 
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typically requires the use of isotopically enriched protein (e.g. 14N → 15N, 12C → 13C, 1H 
→ 2H) and high protein concentrations to mitigate the inherently low sensitivity of the 
technique.85 
 
XRD utilizes the diffraction patterns of an ordered (crystalline) material to obtain 
structural information.93 To perform XRD, a sample of interest must first be crystallized, 
after which it is subjected to X-ray radiation. The scattering of these X-rays by the electrons 
of each atom produce a characteristic diffraction pattern, from which the three-dimensional 
electron density map can be determined. Both bonding and atomic coordinates can be 
inferred from the electron density at a resolution ca. 1 Å (or even slightly lower).94 A major 
limitation of XRD is the immense difficulty in growing protein crystals of sufficiently high-
quality.95 
 
Cryo-EM is a high-resolution imaging technique that utilizes an electron beam to 
elucidate protein structures.96,97 Samples are prepared by first spreading solubilized protein 
across a grid. This is followed by flash-freezing to form a thin layer of vitreous ice 
embedded with protein.98 The sample is then imaged by electron microscopy. By 
combining images from many viewing angles and protein orientations, three-dimensional 
protein structures can be reconstructed. Although sub-Å resolution is theoretically 
obtainable via cryo-EM, a number of practical challenges (e.g. sample integrity, detector 
efficiency) currently preclude this limit from being reached.98 
 
 
1.5. Mass Spectrometry and Associated Techniques 
Mass spectrometry (MS) is an analytical technique that measures the mass-to-
charge ratio (m/z) of analyte ions in the gas phase. The m/z provides information on the 
chemical composition of a molecule. In comparison to other analytical techniques, MS has 
the advantages of high sensitivity and low sample consumption. The basic design of a mass 
spectrometer includes three primary components: 1) an ion source that converts analytes to 
ions, 2) a mass analyzer that differentiates ions by m/z, and 3) a detector to record the ions. 
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Due to the plethora of options in these three components, an assortment of instrumental 
designs are possible, with specific designs tailored to the types of analytes being studied. 
 
1.5.1. Electrospray Ionization Mass Spectrometry (ESI-MS) 
In the context of protein analysis, the most commonly used ionization technique is 
electrospray ionization (ESI), although other techniques (e.g. matrix-assisted laser 
desorption/ionization, MALDI) are also available.99 ESI is particularly well-suited for 
proteins and other biological macromolecules.100–102 In ESI, an analyte solution is 
introduced into a conductive capillary, and a high positive voltage (although negative 
voltages are used for some applications) is applied. A Taylor cone is formed at the capillary 
tip, from which charged, analyte-containing droplets are emitted.103–105 After a number of 
fission and desolvation events, gaseous charged analytes are eventually produced, which 
can then be introduced into the mass spectrometer.106,107 The ESI process generally 
produces multiply charged, protonated species of the form [M+zH]z+, where M is the 
molecular weight of the neutral analyte, and z corresponds to the number of excess protons, 
i.e. the charge state. 
 
Several models have been proposed to describe the process in which proteins 
emerge from charged ESI droplets.104 Globular, native proteins are thought to follow the 
charged residue model (CRM).108,109 In the CRM, the protein remains solvated within the 
droplet core while excess water and/or charge is shed by evaporation or fission events. This 
process continues until the protein ion is fully desolvated. Under these “native ESI” 
conditions, the observed protein charge state (zR) can be approximated by the Rayleigh 
limit of an equivalently sized ESI droplet110 
 
 𝑧𝑅 =  
8𝜋
𝑒
√𝜀0𝛾𝑟
3  (1.1) 
 
where e is the elementary charge, ε0 is the vacuum permittivity, γ is the surface tension, 
and r is the droplet radius.  
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In contrast to their native counterparts, unfolded proteins tend to exhibit much 
higher charge states.111–113 The chain ejection model (CEM) has been proposed to explain 
this behavior.114–116 In the CEM, the unfolded protein chain migrates to the surface of the 
ESI droplet, where Coulombic repulsion promotes the gradual ejection of the protein chain 
off of the droplet surface. Electrostatic forces promote the migration of H+ from the ESI 
droplet to the nascent chain, until the highly charged protein is eventually fully ejected 
from the ESI droplet. 
 
 
ESI-MS offers several advantages for protein analysis. Firstly, ESI represents a 
“soft” ionization technique, in that covalent bonds are not broken by the ionization process. 
This is in contrast to “harsh” ionization techniques such as electron impact117 where 
analytes often fragment. Under properly optimized conditions, even non-covalent 
interactions can be retained during ESI, allowing ESI-MS to provide direct information on 
protein-ligand118,119 and protein-protein120–123 interactions. Secondly, ESI-MS is amenable 
to a very broad mass range (~102 – 106 Da); small molecular weight (MW) analytes are not 
obscured by chemical noise as is the case with MALDI124, while large MW analytes 
become multiply charged (z >> 1), lowering the observed m/z to levels tractable for 
common mass analyzers. Thirdly, ESI can be easily coupled with liquid chromatography 
(LC), facilitating the analysis of complex biological protein mixtures, e.g. for proteomic 
applications.125–128 
 
 
1.5.2. Mass Spectrometers for Protein Analysis 
For the analysis of proteins and other biomolecules, tandem mass spectrometry 
(MS/MS) experiments are often essential. In MS/MS, ions are fragmented in the gas phase, 
and the mass spectrum of the fragment ions is monitored to obtain information on chemical 
structure.129 The prototypical example of a tandem mass spectrometer for biomolecular 
analysis is a triple quadrupole mass spectrometer (QqQ-MS).130 Quadrupoles are devices, 
composed of two pairs of parallel conductive rods, that can act as ion mass filters.131,132 
Depending on the RF and direct current (DC) voltages applied to the rods, only specific 
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m/z values successfully traverse the quadrupole, while other species are filtered out. These 
voltages can be ramped, allowing a range of m/z values to be swept across to generate a 
mass spectrum. Quadrupoles can also be operated as broadband (“RF-only”) ion guide, 
allowing ions of all m/z to traverse through the device. A QqQ-MS is composed of three 
quadrupoles (Q1, q2, and Q3) that are arranged sequentially (Figure 1-4A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-4. (A) Schematic diagram of a QqQ-MS. Each quadrupole is labeled according 
to its standard function in MS/MS. The ion path is shown in blue. (B) Illustration of a 
standard MS/MS experiment. Analyte ions are shown as coloured ovals. The ion depicted 
in green is the target of MS/MS analysis.  
A
B
+
+
+
Mass Select + Fragment +
+ +
+
Scan +
++
+
m/z
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A multitude of MS/MS experiments can be performed using a QqQ-MS.133 In the 
archetypal MS/MS experiment (fragment ion scan, Figure 1-4B), Q1 is used as a mass filter 
to select an ion of interest to be fragmented (called the “precursor ion”). Next, q2 is used 
as a fragmentation cell to activate the ion. Collision-induced dissociation (CID) is the most 
commonly used fragmentation technique, although other activation methods (e.g. electron- 
or photon-based) have also been developed.134 For CID experiments, q2 is filled with an 
inert gas such as Ar. A potential difference is then applied across q2, accelerating the 
analyte ion through the collision gas. Repeated collisions between the analyte and 
background gas results in vibrational heating of the analyte until fragmentation occurs. Q3 
is then scanned across the m/z range to generate a mass spectrum of the produced fragment 
ions. Finally, the ions are detected. An electron multiplier is typically used for this purpose, 
which detects ions by converting ion impact events to electrical signals which are 
subsequently amplified.135 The output of this experiment is a mass spectrum of all fragment 
ions produced by a particular precursor ion (i.e. a tandem mass spectrum). 
 
Many modern tandem mass spectrometers are derived from the basic QqQ-MS 
design.133 Common alterations replace Q3 with a higher resolution mass analyzer. One 
such configuration is a quadrupole time-of-flight (Q-TOF) mass spectrometer, where Q3 
is replaced with a time-of-flight (TOF) mass analyzer.136,137 A TOF measures m/z by first 
applying a high voltage pulse that accelerates the ions. The ions are then allowed to traverse 
a field-free region. The amount of time, tflight, for an ion to traverse this region can be related 
to m/z by 
 
 
𝑡𝑓𝑙𝑖𝑔ℎ𝑡 =  
𝐷
√𝐸𝑑𝑒
× √
𝑚
𝑧
 
(1.2) 
 
 
where D is the length of the field-free region, E is the strength of the initial electric field, 
and d is the length of the region where the accelerating field is applied.138 The resolution 
of a TOF can be greatly enhanced by the use of an ion mirror (a reflectron) to correct for 
variability in the initial ion energies.139  
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A contemporary example of a Q-TOF design is the commercially available 
SYNAPT family of mass spectrometers manufactured by Waters (Figure 1-5).140–142 In the 
SYNAPT platform, Q1 remains essentially unchanged, while the q2 quadrupole is replaced 
with a series of three traveling wave ion guides (TWIGs) in the so-called “TriWave” cell.143 
The first and third TWIGs are functionally similar to a typical collision cell, while the 
central cell is configured to allow traveling wave ion mobility experiments to be performed. 
 
 
 
 
 
Figure 1-5. Representative schematic diagram of the Waters SYNAPT ESI-MS systems 
used in this work. The ion path is shown in blue. 
 
 
1.5.3. Ion Mobility Spectrometry 
Ion mobility spectrometry (IMS) is a gas-phase technique that provides information 
on the conformation (shape) of an analyte.144 In IMS, ions enter a cell filled with neutral 
gas (e.g. He or N2), and an electric field is applied across the cell. As ions traverse the cell, 
collisions with the neutral gas impede their movement. Ions with a larger collision cross 
section (Ω) experience more collisions (drag) from the background gas than ions with a 
smaller Ω, and thus take longer to traverse the cell. IMS separates ions by collisional cross 
section-to-charge ratio (Ω/z).145 If the applied electric field is uniform (as in traditional drift 
tube IMS), Ω can be directly calculated from the drift time (td) via the Mason-Schamp 
equation.146 
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Traveling wave ion mobility spectrometry (TWIMS) is a type of IMS that utilizes 
a series of traveling DC waves to push ions (Figure 1-6), instead of employing a uniform 
electric field.143 In TWIMS, separation occurs when ions experience sufficient drag from 
the background gas to “roll over” the DC wave, impeding their movement until the next 
wave arrives. Many such roll over events take place as ions travel through the TWIMS 
device. Unlike drift tube IMS, Ω cannot be directly calculated from the TWIMS drift time. 
Instead, TWIMS measurements must be empirically calibrated to determine Ω using the 
relationship 
 
Ω
𝑧
=  𝐹 × 𝑡𝑑
𝐵  (1.3) 
 
where F and B are experimentally obtained by performing TWIMS measurements on 
standards where Ω is already known.147,148 
 
 
 
Figure 1-6. Illustration of TWIMS. Left: a series of traveling DC waves (blue blocks, 
numbered) push ions from left to right across the IMS cell. For equally charged ions, ions 
with a larger Ω (light blue ion) will experience more roll-over events (e.g. third row) 
compared to ions with a smaller Ω (red ion). Right: the resulting ion mobilogram from this 
process.  
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1.6. ESI-MS Experiments for Studying Protein Structure 
A versatile toolbox of MS-based techniques has been developed for studying 
protein structure.102 These techniques can be loosely assigned to two categories: those that 
probe primary structure (i.e. sequencing), and those that probe higher order structure (HOS). 
Of the latter class, a distinction can be drawn on how higher order structural information is 
encoded into the mass domain for MS detection, either by 1) covalent labeling of solution 
phase structures, or 2) preserving HOS into the gas phase. 
 
 
1.6.1. Primary Structure: Sequencing 
The primary structure of a protein is given by its amino acid sequence.1 As every 
amino acid (except Leu/Ile) has a unique mass, MS/MS offers a convenient method to 
determine the sequence of a peptide or protein.149 These experiments rely on the fact that 
MS/MS activation predominantly results in fragmentation along the polypeptide 
backbone.150 The amino acid sequence can thus be determined from a tandem mass 
spectrum by the mass differences between successive fragment ions. Similarly, protein 
modifications (e.g. post-translational modifications, oxidative modifications) can be 
localized in an MS/MS experiment by looking for mass differences that do not correspond 
to those of the unmodified amino acids.151 The exact location of cleavage along the 
backbone depends on the MS/MS activation method used.152 For CID, fragmentation 
primarily occurs across backbone amide bonds153 to produce a series of fragment ions 
denoted as b-ions if they contain the N-terminus, or y-ions if they contain the C-
terminus.154–156 Each fragment is numbered according by its proximity to their respective 
terminus (Figure 1-7). 
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Figure 1-7. CID fragmentation of a polypeptide. Each position is labeled with its 
corresponding b/y-ion notation. (A) Generic polypeptide structure overlaid with possible 
CID fragmentation positions. (B) An alternative representation of MS/MS cleavage 
patterns using the heptapeptide Pro-Glu-Pro-Thr-Ile-Asp-Glu. 
 
 
As the fragmentation efficiency and other factors worsen with increasing 
polypeptide length, proteins are often subjected to enzymatic proteolysis to produce 
smaller peptides prior to MS/MS.157 This is termed the bottom-up MS approach. 
Alternatively, it is also possible to perform MS/MS directly on intact proteins without 
proteolysis, termed the top-down MS approach.158–160 Due to its high demands on 
instrument performance and challenging data analysis, top-down MS is comparatively less 
utilized. However, top-down MS experiments provide information not easily obtainable by 
the bottom-up approach, such as combinatorial relationships between different PTMs. This 
enables characterization of protein proteoforms, i.e. the specific molecular form of a 
protein.161 In addition, top-down can probe individual proteoforms in a mixture (versus the 
ensemble measurements inherent to the bottom-up approach).162–164 
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1.6.2. Higher Order Structure: Covalent Labeling Experiments 
Typical MS experiments are performed under conditions where protein HOS is lost 
(e.g. acidified solvent, digestion into peptides), precluding their interrogation. One 
approach, collectively referred to as covalent labeling, circumvents this issue by first 
treating the protein with a reagent that chemically modifies the protein in a way such that 
the pattern of modifications on the protein sequence encodes information on its HOS.165 
Even if the protein structure is disrupted after labeling, the location of the chemical 
modifications do not change. These labels can then be detected and localized by MS(/MS), 
thereby allowing protein HOS to be probed through changes in the mass spectrum. 
Different labeling techniques have developed to probe each level of protein HOS. 
 
The basic form of a covalent labeling experiment is protein footprinting.166 In these 
experiments, protein is exposed to a solution containing a labeling reagent. These reagents 
may be residue-specific (e.g. iodoacetamide for Cys residues)167,168 or be broadly reactive 
(e.g. radical species such as ∙OH).61,169,170 Only residues accessible to the reagent (i.e. the 
solvent-exposed protein surface) are labeled, whereas residues buried within the protein 
are protected and do not react. These experiments provide information on the protein 
tertiary structure. To study quaternary structure, a variant of protein footprinting known as 
crosslinking mass spectrometry (XL-MS) employing bifunctional labeling reagents can be 
used.171–173 These reagents consist of two reactive labeling moieties that are covalently 
linked by an inert spacer with a well-defined length. Upon reaction with the protein, the 
locations of the labels serve as a “molecular ruler” that provides a distance constraint 
between the two labeled sites. The topology of proteins and protein complexes can 
therefore be mapped by the locations of crosslinks.174 XL-MS is often used in conjunction 
with other biophysical techniques (e.g. cryo-EM) to provide additional constraints for 
structural refinement.175,176 
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Hydrogen-deuterium exchange mass spectrometry (HDX-MS) is another popular 
form of covalent labeling.177–182 In HDX-MS, protein is exposed to heavy water (D2O), 
which gradually replaces labile hydrogens (1 Da) with deuterium (2 Da). The rate and 
locations of deuterium uptake is sensitive to dynamic changes in hydrogen-bonding 
networks. As many of these exchange processes are extremely fast, conventional HDX-
MS monitors only the slow-exchanging amide hydrogens of the polypeptide backbone, 
thereby providing information on protein secondary structure. HDX-MS differs 
substantially from the protein footprinting techniques described above in that the 
incorporated deuterium is labile and readily dissociable.183–185 Specialized workflows (e.g. 
acidic proteolysis186,187, low-temperature chromatography188, rapid analysis) must 
therefore be adapted. Challenges also arise in localizing HDX-MS at the residue level due 
to the mobile nature of deuterium in collisionally heated protein or peptide ions 
(“scrambling”).189–192 Nevertheless, these limitations are greatly outweighed by the wealth 
of information gleaned by HDX-MS, particularly regarding protein folding193–195 and 
dynamics.196 
 
 
1.6.3. Higher Order Structure: Native Mass Spectrometry 
Protein HOS can also be directly measured by ESI-MS if experimental conditions 
that promote the preservation of the native protein structure during ionization and 
subsequent transfer into the gas phase are implemented. This approach is often referred to 
as native MS123 and/or “gas phase structural biology”.197 Information such as protein-
ligand198,199 or protein complex stoichiometry120,200,201 is readily obtainable from the ion 
masses observed in native mass spectra. Moreover, the charge state distribution can provide 
insight into protein tertiary structure.113,196 
 
A variety of gas-phase techniques can be performed in conjunction with native MS. 
One particularly powerful example is native IMS, from which protein shape/conformation 
can be inferred via Ω measurements.202,203 This can provide a great deal of information on 
the HOS of a protein, especially when compared against calculated Ω values of candidate 
structures.204,205 The observation that Ω values measured by native IMS are fairly 
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consistent with their condensed phase counterparts have bolstered the view that native-like 
protein structures can be retained in the gas phase.206,207 Native IMS can also monitor 
changes in Ω as a protein is unfolded in the gas phase, forming the basis of collision-
induced unfolding (CIU) experiments.208 In CIU, native protein ions are purposely 
disrupted (e.g. by increasing energy in the collision cell). By plotting Ω as a function of 
ion activation, these CIU profiles can be interpreted in an analogous manner to unfolding 
curves in solution (e.g. monitored by CD spectroscopy), providing thermodynamic 
information. 
 
 
1.7. Scope of Thesis 
The structural basis underlying the peroxidase activity of cyt c remains poorly 
understood. One key aspect that remains unexplored is the potential role of protein 
oxidative modifications in the peroxidase activity of cyt c. It is known that prolonged 
incubation of cyt c with the oxidant (and canonical peroxidase substrate) H2O2 results in 
deactivation of the protein, suggesting that some form of H2O2-induced protein 
modification must be occurring.209–212 However, the chemical nature of these modifications 
and their structural implications have not yet been elucidated. We hypothesize that early 
oxidation events could initially enhance the protein’s peroxidase function. 
 
In Chapter 2, we characterize H2O2-induced oxidative modifications in cyt c by 
applying a suite of MS-based experiments. In doing so, we unravel the critical role that 
these in situ structural changes play in initially triggering the peroxidase activity of the 
protein before eventual inactivation occurs. Through this work, we serendipitously 
discover that certain functionally important oxidative modifications (e.g. on Lys) tend to 
elude detection when using conventional analytical approaches. We propose that these 
modifications may be severely under-reported in the literature. 
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Chapter 3 explores this postulate by conducting studies on cyt c treated with 
chloramine-T, a popular and purportedly well-characterized model system for peroxidase-
activated cyt c. We confirm that the previously unreported oxidation of Lys also occurs 
here, and we uncover that this model system is actually a complex ensemble of structurally 
(and functionally) distinct species that differ by the severity of oxidation. 
 
Chapter 4 expands on the previous chapters by probing the causal factors 
underpinning the production of specific oxidative modification products. We uncover the 
role of heme-mediated catalysis in the formation of certain protein oxidative modifications 
in cyt c, while other transformations proceed via direct interaction with the oxidant. 
 
Chapter 5 utilizes oxidatively-modified cyt c to address the comparability of MS-
derived gas-phase stability measurements to their classical solution phase counterparts. 
Unlike many other systems, we discover that oxidized cyt c shows divergent stability 
behaviour, i.e. destabilization in solution vs. stabilization in the gas phase.  
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Chapter 2. Elucidation of an H2O2-Induced, In Situ Activation 
Mechanism of the Peroxidase Activity of Cytochrome c 
 
 
2.1. Introduction 
Cytochrome c (cyt c) is a highly conserved 12 kDa heme protein that transfers 
electrons in the respiratory chain. Cyt c can also catalyze the H2O2-induced oxidation of a 
wide range of substrates.1-3 This peroxidase activity has attracted considerable attention 
due to its role during apoptosis (programmed cell death).4-9 A key apoptotic pathway 
involves the production of H2O2 in mitochondria.10,11 Cyt c utilizes this H2O2 to catalyze 
the oxidation of cardiolipin in the mitochondrial membrane.4,5,12-14 The damaged 
membrane allows the release of pre-apoptotic factors into the cytoplasm, ultimately 
resulting in cell death.4,6,7,15 Like other peroxidases,16-18 cyt c follows a mechanism where 
H2O2 reacts with the Fe(III) resting state to produce “Compound I”, with a Fe(IV)=O heme 
and an adjacent radical. Subsequent H abstraction from organic substrates regenerates the 
resting state.19 Reactions of the newly formed radicals with O2 then yield stable oxidation 
products.20,21 This cycle usually consumes external substrates, but it also oxidizes the 
protein and causes gradual deactivation.22-25 
 
Classical peroxidases have a five-coordinate heme, where the sixth (distal) site is 
vacant or occupied by loosely bound water.16,18,26 This five-coordinate structure allows for 
Fe-H2O2 interactions which are required for initiating the catalytic cycle.6,8,13,14,26-28 Native 
cyt c is six-coordinate, with Met80 as distal ligand (Figure 2-1A).29 It thus seems 
paradoxical that cyt c would be peroxidase-active.14,30-33 A possible explanation invokes 
transiently formed five-coordinate conformers.2,33-40 Rupture of the distal Met80-Fe bond 
by unfolding,8,37 chemical,2,31,32,35,41,42 or mutational6,14,28,30,36,41,43-45 modifications 
enhances peroxidase activity. 
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The proximal His18-Fe contact in cyt c is quite robust, while the 70-85  loop is 
flexible39 and allows various distal ligation scenarios.2,46 Basic pH produces “alkaline” 
conformers with Lys72, 73 or 79 as distal ligand (Figure 2-1B).33,40,42,47,48 This transition 
can be pushed into the neutral range by various means2,35,42,46,49 that include Tyr67 
modifications.44,46,50 Similarly, cardiolipin binding13,51,52 causes displacement of Met80 by 
Lys or His.12,34,53,54 
 
It is counterintuitive that the aforementioned non-native conformers show enhanced 
peroxidase activity, considering their apparent lack of a vacant sixth coordination site.6,13,26-
28,35,42,49,55 Once again, catalysis may be facilitated by transiently populated five-coordinate 
forms.2,33-40 However, alkaline iron ligation by Lys is more stable than the native Met80-
Fe bond.31,35,39,46 Alkaline conformers should thus have a lower peroxidase activity than 
native cyt c, which is opposite to the observed behavior.15,35,42,49,55,56 Overall, it remains 
unclear why native cyt c and other six-coordinate variants possess apparent peroxidase 
activity. 
 
 
 
 
Figure 2-1. Cyt c crystal structures. The 70-85 Ω-loop is depicted in magenta, key residues 
are highlighted in cyan, iron is displayed in red. (A) Native equine wild-type with Met80-
Fe ligation (PDB 1HRC).29 (B) Alkaline conformer with Lys73-Fe ligation (yeast 
K72A/T78C/K79G/C102S, PDB 4Q5P.)35 (C) Distally de-ligated form (yeast 
K72A/C102S, PDB 4MU8).14  
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Some catalyzed reactions (unrelated to peroxidases) exhibit an initial lag phase. 
Such behavior can have different mechanistic origins, but it often reflects the in situ 
activation of a pre-catalyst.57-59 Intriguingly, a lag phase is also seen for cyt c-catalyzed 
peroxidase reactions.14,40,60 The possible implications of this phenomenon have received 
surprisingly little attention. Cyt c kinetic analyses usually discard lag phase data, while 
focusing on the subsequent steady-state regime.14,44,54,61 Contrary to prevailing views, there 
is a possibility that native cyt c does not exhibit substantial peroxidase activity, and that a 
potent peroxidase is formed only after H2O2-induced modifications. Such activated cyt c 
would likely be five-coordinate, as seen in certain peroxidase-enhanced mutants (Figure 
2-1C).14 The occurrence of an H2O2-induced activation step would imply that 
investigations conducted in the absence of H2O2 are unsuitable for deciphering the 
properties of peroxidase-active cyt c. 
 
Here we address the issues outlined above by performing time-resolved 
experiments on the consequences of H2O2-cyt c interactions. We interrogate H2O2-induced 
structural changes by coupling catalase quenching assays with spectroscopic techniques, 
as well as mass spectrometry (MS)-based peptide mapping, covalent labeling, and top-
down assays. Our data suggest that unmodified cyt c exhibits minimal peroxidase activity. 
H2O2 causes highly selective covalent modifications that produce five-coordinate 
proteoforms with enhanced peroxidase activity. These findings resolve the apparent 
structure-function mismatch by uncovering a previously unrecognized H2O2-induced 
activation process.  
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2.2. Materials and Methods 
2.2.1. Materials. 
Horse heart ferri-cyt c, guaiacol (o-methoxyphenol)62, chloramine-T (N-chloro-4-
toluol-sulfonamide)63, and Girard’s reagent T (GRT, carboxymethyl-trimethylammonium-
hydrazide chloride)64 were from Sigma (St. Louis, MO). Unless specified otherwise, 
solutions contained 10 μM cyt c in 65 mM aqueous potassium phosphate buffer at pH 7.4. 
The H2O2 concentration employed here (500 M, unless noted otherwise) falls within the 
range used for earlier assays14,40,60 and is physiologically relevant as the mitochondrial 
H2O2 concentration can reach ~10-4 M at the onset of apoptosis.11 All experiments were 
conducted at 22  2 C. 
 
2.2.2. Optical Spectroscopy. 
UV-Vis spectra were acquired on a Cary-100 instrument (Varian, Mississauga, ON). 
For measurements at 695 nm the protein concentration was raised to 40 μM. Peroxidase 
kinetics were measured by tracking the oxidation of 9 mM guaiacol in the presence of 1 
μM cyt c. Reaction rates (μM guaiacol oxidized s-1) were determined62 with ε470 = 26.6 
mM-1 cm-1 for the tetraguaiacol product. Circular dichroism (CD) spectra were recorded on 
a J-810 spectropolarimeter (JASCO, Easton, MD). For probing H2O2-induced structural 
changes, UV-Vis data were recorded on-line (20 s per spectrum). CD scans were slower 
(~20 min per spectrum), requiring quenching of the samples with 0.1 μM catalase prior to 
data acquisition. 
 
2.2.3. Protein Samples. 
For MS, 100 μL aliquots were removed from the reaction mixture at selected time 
points, followed by catalase quenching. NMR samples were prepared identically, but in 
D2O. In addition, NMR samples were concentrated to 100 μM using 10 kDa MWCO 
centrifuge filters (Millipore, Etobicoke, ON). Carbonyl labeling was performed by 
incubating 10 μM cyt c in buffer with 80 mM GRT65 for 3 hours at room temperature. The 
reaction was halted by exchange into GRT-free buffer using 10 kDa MWCO filters. 
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2.2.4. NMR Spectroscopy. 
1H-NMR data were collected at 25˚C using a Varian Inova 600 MHz spectrometer 
using a spectral width of 50,000 Hz and an acquisition time of 0.4 s. 2,2-dimethyl-2-
silapetane-5-sulphonate served as internal reference. A weak pre-saturation pulse was 
applied during the 0.1 s recycle delay to suppress the residual water signal. Data were zero 
filled to 132 K, processed using line broadening factors of 2.5 or 10 Hz, and baseline 
corrected. 
 
2.2.5. Mass Spectrometry. 
MS was performed on a Synapt G2 ESI mass spectrometer coupled to a UPLC 
(Waters, Milford, MA). Intact cyt c was analyzed using a C4 desalting column. For top-
down MS/MS, 16+ ions were quadrupole selected, followed by CID in Ar. [Fe(III) cyt c + 
15H]16+ isotope distributions66 were simulated using ProteinProspector (UCSF). Tryptic 
peptides were generated using MS-grade modified trypsin (Promega, Madison, WI) in a 
50:1 cyt c/trypsin ratio. Digests were incubated overnight at 37°C. Peptides were analyzed 
by LC/MS using a C18 column. Peptides were identified using data-dependent acquisition 
and MSE. For quantitating oxidative modifications in tryptic peptides 2.5 μM bradykinin 
was added to each sample as internal standard after digestion.67 Normalized peptide 
intensities N(t) were calculated as a function of H2O2 incubation time t as N(t) = I(t) / Ibrad, 
where I(t) is the signal intensity of an unmodified tryptic peptide at time t, and Ibrad is the 
bradykinin intensity. In analogous fashion, Ncontr data were generated for unoxidized 
control samples. The extent of oxidation can then be expressed as “fraction oxidized”, fOX(t) 
= (1 – [N(t)/Ncontr]).67 Monitoring the depletion of unoxidized peptides ensures robust fOX 
data even if some of the products are difficult to detect.67  
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2.3. Results and Discussion 
2.3.1. Peroxidase Kinetics. 
The peroxidase activity of cyt c can be probed by monitoring the oxidation of 
chromophoric substrates such as guaiacol in the presence of H2O2.1,28,35,62,68 Without 
catalyst there was no evidence of product formation, whereas oxidation proceeded readily 
after cyt c addition (Figure 2-2, black trace). The guaiacol kinetics exhibited three stages 
(Figure 2-2, red trace): (i) a lag phase during which the rate gradually increased from ~zero, 
(ii) a linear steady-state region, and (iii) a region during which the rate declined. The third 
stage reflects oxidative deactivation of cyt c (Figure 2-3).23,24 Lowering the H2O2 
concentration slowed the overall progression (Figure 2-4). A lag phase was also seen for 
the oxidation of substrates other than guaiacol (Figure 2-5). 
 
 
 
 
 
 
 
 
Figure 2-2. Peroxidase activity of cyt c measured by guaiacol oxidation (9 mM) in the 
presence of 500 μM H2O2 in phosphate buffer at pH 7.4. A fit to the linear region (solid gray 
line) yields a reaction rate of 0.027 μM s-1.  
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Figure 2-3. Peroxidase activity of cyt c measured after pre-incubation of the protein with 
500 μM H2O2 for 15 min, prior to addition of guaiacol. No product formation is detectable 
under these conditions as a result of oxidative self-degradation. 
 
 
 
 
Figure 2-4. Peroxidase activity of cyt c measured by probing the oxidation of guaiacol as 
in Figure 2-2 but in the presence of 50 μM H2O2 instead of 500 μM. A fit to the linear 
region (solid black line) yields a reaction rate of 0.0013 μM s-1.  
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Figure 2-5. Peroxidase activity of cyt c probed by fluorescence bleaching of 10 M 
rhodamine 6G (R6G) in the presence of 500 μM H2O2. A three-stage kinetic progression 
similar to that of guaiacol is observed (see Figure 2-2). Fluorescence experiments were 
performed on a Fluorolog-3 fluorimeter (Horiba Jobin Yvon; Edison, NJ), using an 
excitation wavelength of 526 nm, and an emission wavelength of 555 nm.  
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A lag phase in the peroxidase kinetics of cyt c has been reported previously,14,40,60 
but this phenomenon has received very little attention. One study60 attributed the lag phase 
to Fe(II) → Fe(III) conversion, but this scenario can be excluded for the Fe(III) samples 
used here (Figure 2-6). We nonetheless agree with the basic conclusion of ref. 60 that the 
lag phase suggests some form of pre-catalyst activation.57-59 Figure 2-2 and Figure 2-5 still 
leave room for alternative explanations, but when considering the MS data discussed below 
it will become clear that covalent modifications are indeed required for converting cyt c to 
an active peroxidase. 
 
 
 
 
 
 
 
Figure 2-6. UV-Vis absorption spectrum of cyt c used in this work, prior to H2O2 exposure. 
These data confirm the oxidation state of the heme iron as Fe(III). The measured spectral 
maxima (red) are consistent with literature values for the Fe(III) form, whereas there is no 
match with the peak positions expected for Fe(II) cyt c (black).1,2  
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2.3.2. Spectroscopic Evidence for H2O2-Induced Structural Changes. 
Upon exposing cyt c to H2O2 the CD amplitude at 222 nm decreased by ~30% 
within 20 min, implying a loss in -helicity (Figure 2-7A).69 A Soret shift from 409 nm to 
406 nm indicated alterations in the heme environment, while a declining Soret intensity 
was caused by heme degradation (Figure 2-7B).23,24,70,71 Disappearance of the 695 nm band 
(A695)72 revealed rupture of the Met80-Fe bond (Figure 2-7C). A695 declined more 
rapidly than the Soret peak, implying that the loss of Met80 ligation is triggered by events 
other than heme degradation. 
 
An important question is whether the loss of Met80 ligation is followed by the 
formation of alternative distal contacts. 1H-NMR allows fingerprinting the Fe environment 
due to paramagnetic proton shifts.40,42,46,73,74 After 5 min in H2O2 several 1H signals 
associated with native cyt c had significantly dropped in intensity, including those of Met80 
(Figure 2-8). This matches the UV-Vis-detected loss of Met80-Fe ligation (Figure 2-7C). 
The NMR spectra provided no evidence for alternative Fe ligation scenarios, e.g. distal Lys 
contacts would cause conspicuous peaks in the 12-25 ppm range.46,74 No such signals were 
apparent in our NMR data, nor was there evidence that other ligands replace Met80. It is 
concluded that H2O2 triggers the formation of conformers with a vacant sixth coordination 
site. Considering that peroxidases require a five-coordinate heme,6,8,13,14,26-28 our 
spectroscopic data strongly suggest that the peroxidase activity of cyt c arises from five-
coordinate species produced in the presence of H2O2.  
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Figure 2-7. Spectroscopic evidence for cyt c time-dependent structural changes in 500 M 
H2O2. (A) Far-UV CD spectra. (B) UV-Vis absorption spectra of the heme Soret band. (C) 
Absorption spectra of the A695 band, which reports on the Met80-Fe interaction. For better 
visualization spectra in panel C were baseline shifted such that they all had the same 
absorbance at 670 nm.  
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Figure 2-8. 1H-NMR spectra of cyt c. (A) No H2O2 added. (B) After 5 min of incubation 
in 500 M H2O2 and subsequent catalase quenching. Peaks were assigned and denoted 
according to Feng et al.73 A global loss in signal intensity after H2O2 incubation is 
consistent with partial heme degradation, as also confirmed by optical data of Figure 2-7.  
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2.3.3. H2O2-Induced Modifications Probed by Mass Spectrometry. 
Intact protein mass spectra acquired during H2O2 incubation revealed a gradually 
declining signal amplitude (Figure 2-9A-D), concomitant with dramatic peak broadening 
(Figure 2-9E-H). The t = 0 spectrum displayed a single major isotope distribution 
corresponding to unmodified cyt c, denoted as “M0” in Figure 2-9E. After 10 min the mass 
distribution was split into numerous signals, arising from covalent oxidative modifications 
(M1, M2, M3, ..., Figure 2-9F-H). The spacing between successive Mi species 
corresponded to mass differences of 14 - 16 Da. Similar patterns have previously been 
reported for other proteins after exposure to different types of oxidants.22,32,75,76 
 
 
 
Figure 2-9. (A-D): Cyt c mass spectra acquired after varying H2O2 incubation times. (E-
H): 16+ charge state region. M0 denotes unmodified protein. M1, M2, .... refers to 
oxidatively modified forms. Protein (10 μM) and H2O2 (500 M) were incubated in 
phosphate buffer at pH 7.4.  
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2.3.4. Peptide Mapping of Oxidation Patterns. 
LC-MS was applied to monitor H2O2-induced modifications via analyses of tryptic 
peptides. The resulting fOX data (Figure 2-10) were visualized as color maps (Figure 2-11). 
T13-T15 (residues 61-79) consistently stood out as the most heavily oxidized region. This 
region covers the distal side of the heme, i.e. the catalytically active region. Considering 
the critical role of the Met80-Fe bond for catalytic activity,8,32,41,56,77 it might have been 
expected that the Met-80 containing T16 would be most strongly oxidized. However, T16 
generally showed lower fOX than T13-T15 (Figure 2-11). 
 
H2O2-induced modifications were further characterized by subjecting tryptic 
peptides to tandem MS (Figure 2-12). Detected oxidation sites included Tyr48 (+16), 
Trp58 (+16,+32), Met80 (+16,+32) and a +32 Da shift within residues 33-35 (His-Gly-
Leu). T5 could not be probed due to the heterogeneity of heme degradation 
products.23,24,70,71 Surprisingly, we were unable to detect T13-T15 oxidation products after 
cyt c incubation in H2O2. Chymotrypsin and GluC were tested as alternative proteases, but 
the results were inconclusive (data not shown). Oxidized T13-T15 peptides were readily 
observable after alternative treatments were performed as controls (Figure 2-13). This 
implies that H2O2 causes specific T13-T15 modifications that interfere with MS detection. 
The nature of these modifications will be discussed below. 
 
The H2O2-induced oxidation patterns of Figure 2-11 are very different from those 
observed after exposing cyt c to free OH in bulk solution.78 In the latter case, oxidation 
primarily affects solvent-accessible residues.20 In contrast, modifications formed under the 
conditions of the current work are heme-catalyzed,19 such that buried sites adjacent to the 
porphyrin are particularly prone to oxidation.22-25 Free OH is not involved in these 
peroxidase processes.19  
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Figure 2-10. Fraction oxidized (fOX) plots of tryptic cyt c peptides following incubation in 
500 M H2O2 and catalase quenching. Standard deviations of two replicates are depicted 
as error bars.  
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Figure 2-11. (A) Tryptic peptide mapping, displaying the extent of oxidative modifications 
as a function of H2O2 incubation time. Colors indicate the fraction oxidized, fOX, ranging 
from blue (little oxidation) to red (heavily oxidized). Met80 is highlighted as spheres. 
Regions for which no structural data were obtained are colored grey (sequence coverage 
89%). (B) fOX data for t = 5 min mapped to the cyt c sequence. Detected tryptic peptides 
are annotated as T1, T4, etc. Peptides T9-10, T13-14, and T18-20 arise from missed 
cleavage sites. T5 includes the heme.  
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Figure 2-12. Representative tandem mass spectra of tryptic peptides, illustrating the 
identification of oxidation sites. MS/MS data of oxidized peptides were obtained after 30 
min of cyt c incubation in 500 M H2O2, followed by tryptic digestion. (A) Unmodified 
T15. (B) T15 oxidized at Met80 (MetO formation, +16 Da, bold/underlined). (C) 
Unmodified T9-10. (D) T9-10 oxidized at Tyr48 (+16 Da, bold/underlined).  
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Figure 2-13. Representative tandem mass spectra of tryptic cyt c peptides obtained in 
control experiments. (A): Y67 oxidation (+16 Da) generated after incubation of pre-
digested tryptic peptides in H2O2 (30 min). (B) M65 oxidation (+16 Da) generated after cyt 
c oxidation using chloramine-T.56 Chloramine-T treatment was performed by adding 2.5 
mM of the oxidant to buffered protein solution, followed by room temperature incubation 
for 1 hour. Reactions were stopped by exchange into phosphate buffer using 10 kDa 
MWCO centrifuge filters that were spun 3 times, each cycle being 15 minutes at 10 kG.  
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2.3.5. Chemical Deconvolution. 
Several mechanistic aspects can be uncovered by examining the intact protein mass 
envelope. Figure 2-14A-C displays the mass distribution of unmodified cyt c. Oxidative 
modifications M1, M2, ... formed upon H2O2 exposure are highlighted in Figure 2-14D. 
The M1 population is of key interest because it carries the initial modifications. The M1 
isotope envelope was ~50% wider than that of unmodified cyt c, and the center of M1 was 
shifted roughly -2 Da relative to a hypothetical [cyt c + O] species (Figure 2-14E). These 
characteristics imply that M1 encompasses different oxidation products with slightly 
different masses. 
 
 
 
 
Figure 2-14. Mass spectra of the 16+ charge state for unmodified cyt c (A-C), after 5 min 
in H2O2 (D-F), and after 5 min in H2O2 with subsequent GRT labeling (G-I). Column 2 
shows close-ups of the region comprising M0 (unmodified protein) and M1 (first 
modification peak), with simulated isotope envelopes for cyt c and [cyt c + O]. Column 3 
shows the GRT-labeled Mi forms. Carbonyl-depleted M1 after GRT labeling is denoted as 
M1* (panel H).  
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Chemical deconvolution was applied to tackle the heterogeneity of the H2O2-treated 
protein. GRT selectively tags reactive carbonyl groups formed by oxidation (i.e. not those 
of endogenous amides or carboxylates, Figure 2-15).64,65,79,80 By shifting carbonylated 
species into a mass range that differs from that of non-carbonylated forms, GRT labeling 
reveals proteins carrying other types of modifications. Without H2O2 treatment cyt c did 
not incorporate GRT (Figure 2-16D). In contrast, extensive GRT labeling took place for 
M1, M2, ... formed in the presence of H2O2 (Figure 2-14I). This observation reveals that 
H2O2 causes cyt c carbonylation, consistent with immunological data.81 The extent of 
carbonylation increased with H2O2 exposure time (Figure 2-16). Reaction products M1, 
M2, ... tagged with one or two GRT moieties were clearly discernible in the spectra (Figure 
2-14I, Figure 2-17). The relatively low signal intensity of these products likely reflects the 
aggregation propensity of carbonylated proteins.82 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-15. Assay for Lys carbonylation, i.e. oxidative deamination to aminoadipic 
semialdehyde, Δm = -1.032 Da. Covalent attachment of the hydrazide-containing label, 
Girard’s Reagent T (GRT) takes place via Schiff base formation. This results in Δm/z = 
+112.063, when going from a Lys+-containing reactant to the GRT-labeled product. The 
quaternary ammonium group adds a permanent cationic moiety to facilitate MS detection.  
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Figure 2-16. Intact protein mass spectra of cyt c (16+) following H2O2 incubation and 
subsequent labeling with GRT. (A) unmodified cyt c. (B, C) After increasing lengths of 
H2O2 incubation. (D) – (F) show spectra of the corresponding samples after GRT labeling. 
Note that GRT labeling is detectable only after H2O2 exposure, reflecting the formation of 
reactive carbonyl groups. 
 
 
 
Figure 2-17. Mass spectral data for cyt c following 10 min incubation in 500 M H2O2 and 
subsequent GRT labeling. The populations of singly and doubly-adducted GRT are 
highlighted in magenta and orange, respectively. (A) Overview of the 16+ range. (B) 
Expanded view of the m/z range corresponding to GRT addition.  
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In addition to unmodified cyt c (M0), carbonyl-depleted cyt c showed “M1” as the 
only major signal (Figure 2-14G). The centroid of this carbonyl-depleted M1 (Figure 
2-14H) was shifted by roughly +2 Da relative to the original M1 (Figure 2-14E). We will 
refer to this sub-population as M1*. Comparison with a simulated isotope envelope reveals 
that M1* primarily consists of proteins with the composition [cyt c + O] (Figure 2-14H). 
 
The aforementioned findings demonstrate that M1 (Figure 2-14E) comprises [cyt c 
+ O], along with carbonylated species that are 1 to 2 Da lower in mass. Lys conversion to 
aminoadipic semialdehyde (R-CH2-NH2 → R-CHO) is the only documented carbonylation 
pathway with a mass shift of -1 Da.20,79 Thus, we propose that M1 contains [cyt c + O] 
where 0, 1, or 2 of the 19 Lys side chains have undergone carbonylation. Tyr dimerization 
(-2 Da)83 and other crosslinking modifications20,79 in M1 can be excluded, because they 
would not convey GRT reactivity. Thus, the various oxidative modifications detected by 
peptide mapping (at Tyr48, Trp58, Met80 etc., see above) must reside in the more highly 
oxidized species Mi, with i > 1. Likely, these highly oxidized species are also subject to 
Tyr dimerization, as suggested in previous work.81,83 
 
Figure 2-14 also provides information regarding the temporal sequence of oxidation 
events. [cyt c + O] is susceptible to carbonylation, seen from disappearance of -1 and -2 
Da mass shifts by GRT labeling, and from the formation of [M1+GRT] and [M1+2GRT] 
(Figure 2-14I, Figure 2-16). In contrast, M0 is effectively inert against carbonylation, 
evident from the fact that neither H2O2 nor GRT treatment affect the M0 mass distribution 
(Figure 2-14E, H), and from the lack of a discernible [M0 + GRT] signal in Figure 2-14I. 
Hence, carbonylation occurs after an initial +O modification. 
 
The carbonyl-depleted and the carbonylated sub-populations show major 
differences in their degree of self-oxidation, which serves as a proxy for the level of 
peroxidase activity (Figure 2-18). The carbonyl-depleted sub-population is dominated by 
M1* (incorporation of a single oxygen, Figure 2-18A). In contrast, carbonylated cyt c has 
its maximum at [M2+GRT] with major contributions from [M3+GRT] and beyond (with 
2, 3, ... incorporated oxygens, Figure 2-18B). The fact that carbonylated cyt c exhibits more 
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extensive self-oxidation, implies that carbonylation enhances peroxidase activity relative 
to unmodified cyt c and [cyt c + O]. In other words, Figure 2-18 provides unequivocal 
proof that chemical modifications cause peroxidase activation of cyt c, i.e. the transition of 
a low activity catalyst to the active enzyme. Our data imply that this activation follows a 
sequential mechanism, with incorporation of a single oxygen as the initial step. The [cyt c 
+ O] formed in this way retains a low peroxidase activity, similar to that of the unmodified 
protein. Peroxidase activation takes place upon subsequent carbonylation. 
 
 
 
 
 
 
 
Figure 2-18. Comparison of oxidation patterns after 5 min in H2O2 followed by GRT 
labeling, (A) The carbonyl-depleted protein is dominated by M0 and M1*. Other oxidation 
peaks have very low intensity. (B) The carbonyl-containing population exhibits a 
dramatically elevated oxidation level. Peak maxima of oxidatively modified species are 
highlighted, annotation is as in Figure 2-14.  
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2.3.6. Top-down MS. 
To pinpoint the initial [cyt c + O] modification(s) we performed top-down 
experiments, i.e. tandem MS without prior protein digestion (Figure 2-19).84 This approach 
allowed the interrogation of specific species within the heterogeneous mix formed during 
H2O2 exposure. Top-down data (see Figure 2-20 for full spectra) were acquired for three 
precursor ions, the M0 unmodified control (Figure 2-14B), M1 (Figure 2-14E), and 
carbonyl-depleted M1* (Figure 2-14H). The b and y fragments provided complete 
sequence coverage (Figure 2-19A). Dissociation of both M1 and M1* resulted in 
unmodified C-terminal fragments up to y37, whereas a +16 Da shift was seen from y38 
onwards (Figure 2-19B). This pattern identifies Tyr67 as the oxidation site in [cyt c + O]. 
Other oxidation sites were absent, revealing that M1* is just a single proteoform. The top-
down identification of Tyr67 oxidation is also consistent with the peptide data of Figure 
2-11, which mapped the most prevalent early modification to residues 61-79. 
 
Unfortunately, top-down fragmentation did not reveal the nature of carbonylation 
sites, as none of the M1 fragments displayed mass shifts related to Lys carbonylation (or 
other non-Tyr67 oxidation events). GRT labeling revealed that M1 represents a mix of 
carbonylated and non-carbonylated species. Evidently, the fragmentation of carbonylated 
proteins was suppressed in our top-down experiments. We attribute this effect to the 
inability of carbonylated Lys to bear charge, thereby inhibiting the gas phase dissociation 
of amide bonds85,86 or favoring dissociation pathways that do not conform to canonical b/y 
patterns.87 Peptide mapping using trypsin, chymotrypsin, and GluC was applied as outlined 
above, but unfortunately those experiments also did not yield direct information regarding 
the location of carbonylation sites.  
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Figure 2-19. Top-down MS/MS data produced by CID of cyt c16+. (A) Sequence with 
observed fragmentation sites. (B) Representative ion signals after fragmentation of M0 
(unmodified protein, m/z 773.5, top row), M1 (first modification peak, center row, m/z 
774.4), and M1* (first modification peak after GRT labeling, m/z 774.5). Peaks are labeled 
following standard b and y ion notation. Each panel also shows a simulated isotope 
distribution, corresponding to either the unmodified protein (circles) or the +O species 
(diamonds). The +O Da modification can be assigned to Y67.  
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Figure 2-20. Complete top-down tandem mass spectra produced by CID of cyt c16+. The 
data of Figure 2-19 are a subset of the spectra shown here. (A) Spectrum obtained after 
fragmentation of (A) M0, (B) M1, and (C) M1* at a collision voltage of 23 V. Panels (D) 
– (F) show spectra obtained for the same precursor ions, but at a slightly elevated collision 
voltage of 26 V.  
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Despite our inability to directly identify the nature of carbonylation sites in M1, 
there is evidence to suggest that Lys72/73 are primarily affected. Carbonylation of these 
residues explains the lack of detectable oxidized peptides in the T13-T15 region. 
Specifically, the high fOX of T15 at early times (Figure 2-11) likely reflects a missed tryptic 
cleavage due to Lys73 carbonylation. Also, Lys72/Lys73 are known to adopt positions 
close to the heme in “alkaline” cyt c,2,40,42,44,46-50 particularly after Tyr67 modifications.35 
The proximity to the reactive iron makes Lys72/Lys73 prime candidates for oxidative 
modifications. Consistent with this view, the spectroscopic properties of H2O2-activated 
cyt c (at t  5 min, Figure 2-7) are close to those of “alkaline” Tyr67Arg cyt c.46 Similarities 
include a Soret maximum at 406 nm, the shape of the CD spectrum with a minimum at 
~206 nm, and loss of A695. The 406 nm Soret signal is compatible with distal ligation by 
OH-/H2O (after H2O2-activation) or by Lys (for Tyr67Arg).35 
 
It is instructive to consider the viability of alternative scenarios, where M1 
represents a mix of two independently formed products, i.e. [cyt c + O] (Tyr67 oxidized, 
+16 Da) and [cyt c + O - 2H] (aliphatic ketone, +14 Da). In such a case Figure 2-18 would 
imply that the +14 Da species is highly prone to self-oxidation, whereas Tyr67 oxidation 
protects the protein against additional modifications. It is difficult to envision such a 
scenario because (i) Tyr67 modifications generally enhance (rather than inhibit) peroxidase 
activity.35,44,46,50 (ii) If Tyr67 were to inhibit self-oxidation M1* should accumulate after 
extended H2O2 exposure, in contradiction with the spectra of Figure 2-9. (iii) +14 Da 
products are generally disfavored relative to other modifications,20,79 while Lys 
carbonylation is highly prevalent during metal-catalyzed oxidation.88 (iv) The top-down 
detection of +14 Da modifications should be straightforward; our data did not provide any 
evidence of such species. All these points argue against the presence of +14 Da 
modifications in M1, reinforcing the view that Tyr67 oxidation leads to an on-pathway 
intermediate (M1*) that undergoes subsequent Lys carbonylation to form M1. 
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2.3.7. Peroxidase Activation Mechanism of Cyt c. 
From the data presented above we can propose a model for the H2O2-induced 
peroxidase activation of cyt c (Figure 2-21). The native state M0 has low peroxidase 
activity because the distal coordination site is occupied by Met80, restricting interactions 
of the iron center with H2O2. The initial modification en route towards the active state is 
Tyr67 oxidation (to 3,4- or 2,4-dihydroxyphenylalanine20). This reaction likely takes place 
in a heme-catalyzed fashion,89 facilitated by transient opening events of the 70-85  loop 
(Figure 1) which represents the most dynamic cyt c region.39 A Tyr67 radical formed in 
the presence of H2O289,90 may be an intermediate of this oxidation step. Tyr67 
modifications are known to destabilize the Met80-Fe bond due to involvement of the Tyr 
side chain in packing interactions and H-bonding. These conditions favor distal heme 
ligation by Lys72/73.44,46,50 Our data suggest that an analogous ligand displacement takes 
place after Tyr67 oxidation, producing M1* where Lys72/73 compete with Met80 for iron 
ligation. M1* transiently accumulates to no more than ~10% of the total protein population 
(Figure 2-18). The lack of discernible Lys-specific 1H-NMR signals (Figure 2-8) indicates 
that iron contacts with Lys72/73 in the M1* state remain fluctional, while the proximity of 
Lys72/73 to the redox-active heme triggers carbonylation. Carbonylated Lys is no longer 
capable of iron ligation, leaving behind a vacant distal coordination site. The five-
coordinate M1 produced in this way represents the nascent peroxidase-active state of cyt c. 
Peroxidase activity is likely retained while additional oxidation events affect Met80, Tyr48, 
Trp58 and other residues (corresponding to M2, M3, ...). Activity is gradually lost as more 
and more of the protein is affected by oxidation. 
 
The modification steps of Figure 2-21 require access of H2O2 and O2 to the protein 
interior. We envision that this access is provided by conformational fluctuations, as noted 
above.39 Such fluctuations will be particularly important for facilitating the initial steps, i.e. 
M0 → M1* → M1. Previous studies already noted the importance of dynamics for the 
peroxidase activity of cyt c,2,33-38,40 but the role ascribed to these fluctuations here is 
different from that envisioned earlier. Other studies implied that native state fluctuations 
per se might produce a five-coordinate population that is entirely responsible for the 
“native state” peroxidase activity. Our observations demonstrate that the peroxidase 
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activity of unmodified native cyt c is low, and that significant substrate turnover takes place 
only after carbonylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-21. Proposed model for the H2O2-induced peroxidase activation of cyt c. MS-
detected proteoforms are denoted along the top. Dotted lines in M0 and M1* indicate 
occasional opening of distal contacts due to protein conformational fluctuations, allowing 
for Fe-H2O2 interactions that are required for activation (oxygen incorporation into Tyr67, 
carbonylation of Lysx). M1, M2, ... represent peroxidase-active species where Fe-H2O2 
contacts are greatly facilitated because the distal coordination site is vacant. The nature of 
“Lysx” could not be determined with absolute certainty in this study, but our data indicate 
that it corresponds to Lys72 and/or Lys73.  
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2.4. Conclusions 
Previous studies did not comprehensively answer the question why native cyt c, 
with its six-coordinate iron, possesses apparent peroxidase activity. The present work 
resolves this conundrum by attributing much of the peroxidase activity to five-coordinate 
species formed in the presence of H2O2. The conversion from a pre-catalyst to peroxidase-
active cyt c is consistent with the observation of a lag phase during substrate 
oxidation.14,40,60 
 
Various reasons may have contributed to the fact that the H2O2-induced activation 
of cyt c has been overlooked in the past. Many earlier studies characterized wild type and 
mutant proteins ex situ, without considering the possibility of H2O2-induced, functionally 
relevant alterations. Also, H2O2 produces a mix of transient proteoforms that are difficult 
to characterize by most techniques. Here we approached the problem from a new angle by 
interrogating catalase-quenched samples in a time-resolved fashion using optical 
techniques and MS. 
 
It is tempting to speculate on the implications of our findings for the role of cyt c 
during apoptosis. Our in vitro data suggest that cyt c within mitochondria might also adopt 
its peroxidase-active state only after oxidative modifications. Specifically, cardiolipin-
bound cyt c with Lys or His ligation12,34,53,54 likely does not represent a form that is highly 
peroxidase-active. Instead, these hexa-coordinate species may be analogous to M1* 
(Figure 8), requiring oxidative modifications to free up the distal coordination site prior to 
becoming an active catalyst. Similarly, engineered six-coordinate constructs might enter 
the sequence of Figure 2-21 at the M1* stage, skipping the initial oxidation event, and 
thereby providing an explanation for their enhanced apparent peroxidase activity.6,13,26-
28,35,42,49,55  
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Chapter 3. Lysine Carbonylation as a Previously Unrecognized 
Contributor to Peroxidase Activation of Cytochrome c in 
Oxidants Other than H2O2 
 
 
3.1. Introduction 
Cytochrome c (cyt c) is a 12 kDa mitochondrial heme protein whose primary role 
is to serve as an electron shuttle in the respiratory chain.1 Cyt c also possesses a second 
biologically relevant function as a peroxidase.2-8 Peroxidases catalyze the oxidation (H 
abstraction) of substrates in the presence of H2O2. Catalytic turnover involves heme cycling 
between the Fe(III) and Fe(IV)=O states.9 The peroxidase activity of cyt c is critical for 
triggering apoptosis (programed cell death) via oxidation of the mitochondrial membrane 
lipid cardiolipin.7,10-12 Apoptosis is an essential process, e.g. for suppressing tumor 
growth.13 
 
Peroxidases require a pentacoordinated heme with a vacant distal coordination site 
where H2O2 can bind, and where the Fe(IV)=O oxygen can be accommodated.14 The heme 
in native cyt c is hexacoordinated, as the distal site is occupied by the Met80 sulfur (Figure 
3-1).15 Dissociation of this Met80-Fe contact is a mandatory prerequisite for converting cyt 
c into a peroxidase.14,16-17 There are different ways to achieve displacement of the distal 
Met80, such as unfolding14, 16 chemical5, 17-20 or mutational modifications,4,7,18,21-26 as well 
as cardiolipin binding.3,27-29 Exposure to basic pH induces the formation of “alkaline” 
conformations where Lys72, 73 or 79 serve as distal ligands instead of Met80.20,30-34 
Chemical or mutational modifications can shift this alkaline transition into the neutral 
range.5,19-20,35-40  
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Figure 3-1. Crystal structure of equine cyt c (PDB 1HRC) with key residues highlighted. 
(A) Side view. (B) Top view. In the native state, the heme co-factor is ligated by Met80 
and His18. Lys72/73 and Lys53/55 represent possible alternative distal ligands that may 
interact with Fe instead of Met80 under certain conditions. The flexible 71-85 Ω loop is 
shown in red.  
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We recently demonstrated41 that H2O2 converts native cyt c into an active 
peroxidase via a reaction sequence that starts with Tyr67 oxidation, followed by 
dissociation of the Met80-Fe contact. Subsequently, Lys72 or 73 occupy the distal 
coordination site. Carbonylation then abrogates the capability of Lys72/73 to serve as Fe 
ligands, thereby generating the free distal site that is required for an active peroxidase.41 
Lys carbonylation corresponds to the oxidation of the -amino group to an aldehyde 
(LysCHO, aminoadipic semialdehyde, M = -1 Da).42-43 
 
The most straightforward method to rupture the Met80-Fe bond is via Met 
oxidation to methionine sulfoxide (MetO). It is widely believed that this oxidative 
modification is sufficient for generating the open distal site that is required for peroxidase 
activation of cyt c in vitro and in vivo.17-18,37-38,44-47 In other words, this Met80-centric view 
envisions a simple causal relationship between MetO formation and peroxidase activity.17-
18,37-38,45-47  
 
A key pillar of the Met80-centric view comes from work on chloramine-T (CT) 
oxidized cyt c (CT-cyt c). CT is a mild oxidizing agent48 that transforms into other reactive 
species in aqueous solution.49 Among these, OCl- appears to be mainly responsible for cyt 
c oxidation, evident from the fact that cyt c exposure to CT and to OCl- causes similar 
effects.17 CT-cyt c is a potent peroxidase.17,37 Several studies have shown that CT-cyt c 
carries a sulfoxide at both Met80 and Met65, while claiming that no other chemical 
modifications are present.17,48,50 These claims go back to amino acid analyses conducted in 
the 1970s, which concluded that CT specifically oxidizes Met, while leaving all other 
residues unmodified (except for -SH groups, which are absent in cyt c).51 Those early 
studies17,48,50-51 cemented the widely held belief that Met80 oxidation, without any other 
covalent changes, generates an active peroxidase.17-18,37,45-47 As a result, CT-cyt c has 
become a widely used model for peroxidase-activated cyt c.17,37-38,47  
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Considering the far-reaching implications of work in this area (including the role 
of cyt c in apoptosis and tumorigenesis),13 it is imperative to fully understand the properties 
of CT-cyt c. Is it true that Met80 oxidation is sufficient for peroxidase activation? Is it true 
that MetO formation is the only CT-induced oxidative modification? Several lines of 
evidence hint at the involvement of additional factors. (1) Disruption of the Met80-Fe bond 
tends to produce “alkaline” ligation scenarios, where even at near-neutral pH the distal site 
becomes occupied by side chains such as Lys72/73.19,35-36,38 These alternative ligation 
scenarios are promoted by the flexible nature of the 71-85 Ω loop (Figure 3-1).52-53 Hence, 
it is not obvious why Met80 oxidation in itself would produce a vacant distal site that is 
required for peroxidase activity. (2) The purported strict selectivity of CT for Met is 
somewhat suspicious, considering that other oxidants can induce various modifications at 
different types of residues.54-58 (3) Typical CT-cyt c literature protocols utilize strong cation 
exchange (SCX) chromatography, which separates proteins according to their positive 
surface charge. Surprisingly, CT-cyt c undergoes SCX fractionation into several distinct 
bands.37-38,47-48 MetO formation does not directly affect charge. The fact that CT-cyt c 
produces several SCX fractions thus suggests that the protein might contain additional, 
hitherto unidentified modifications. The possible existence of such modifications and their 
implications for peroxidase activation have been ignored thus far in the literature. 
 
In this work we critically examined the structure and function of CT-cyt c. Various 
mass spectrometry (MS) techniques were applied to characterize CT-induced covalent 
modifications in unprecedented detail. We were able to pinpoint previously unidentified 
features of the peroxidase activation process. Met80 oxidation alone was found to result in 
low peroxidase activity, because the distal site remained impeded by alkaline-like Lys 
ligation. Only after opening of the distal site by CT-induced LysCHO formation did the 
protein show higher levels of activity. Previous studies on CT-cyt c that assumed a “clean” 
MetO protein have - in all likelihood - inadvertently characterized samples that contained 
both MetO and LysCHO sites. Our findings argue against the prevailing notion that Met80 
oxidation alone is sufficient for peroxidase activation. Instead, Lys carbonylation is a key 
peroxidase co-activator.  
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3.2. Methods 
3.2.1. Materials. 
Horse heart ferricyt c, H2O2, guaiacol (o-methoxyphenol), ammonium acetate, and 
chloramine-T (N-chloro-4-toluol-sulfonamide), were from Sigma Aldrich (St. Louis, MO). 
Solvents were from Fisher Scientific (Nepean, ON). Potassium phosphate was supplied by 
Caledon Laboratories (Georgetown, ON), and MS-grade modified trypsin was from 
Promega (Madison, WI). All experiments were conducted at 22  2 C. 
 
3.2.2. Preparation of CT-cyt c. 
Treatment of cyt c with CT was performed as described,37 with minor alterations. 
Briefly, a 5 mM aqueous solution of CT was added to 1 mM cyt c of (both in 50 mM Tris 
buffer, pH 8.4) in a 1:1 volume ratio and reacted at room temperature for 3 hours. The 
reaction was then halted by dialysis against 10 mM potassium phosphate (pH 7.4) using 10 
kDa MWCO filters (EMD Millipore, Etobicoke, ON). The CT-cyt c produced in this way 
was either used directly or subjected to SCX chromatography using a 5 mL HiTrap 
sulfopropyl (SP) cartridge (GE Healthcare) on an ÄKTApurifier FPLC. The HiTrap SP 
column was conditioned as per manufacturer instructions, and proteins were loaded at 0.25 
mL min-1. The column was then washed with H2O until the absorbance (280 nm) reached 
the pre-loading baseline. SCX elution was performed using a linear gradient of 500 mM 
ammonium acetate (pH 9) over 5 column volumes while collecting the eluent in 1 mL 
fractions.  
 
3.2.3. Optical Spectroscopy. 
UV-Vis spectra were acquired on a Cary-100 spectrophotometer (Varian, 
Mississauga, ON). Soret measurement were performed on 10 μM protein solutions in 50 
mM potassium phosphate buffer (pH 7.4). Absorbance measurements at 695 nm were 
performed at 40 μM protein. Peroxidase activity was measured as described59 by tracking 
the oxidation of 9 mM guaiacol in the presence of 100 M H2O2. Additional experiments 
were also conducted using 500 M H2O2. This H2O2 concentration range is in line with 
previous work,7, 32 and it is comparable to physiological H2O2 levels at the onset of 
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apoptosis.60 In these assays the formation of tetraguaiacol was probed by UV-Vis at 470 
nm.59 All activity assays contained 1 μM protein as determined by absorption 
measurements at the Soret maximum. Kinetic measurements at each H2O2 concentration 
were repeated in triplicate. Circular dichroism (CD) spectra were recorded on a Jasco J-
810 spectropolarimeter (JASCO, Easton, MD), on 10 μM protein solutions in phosphate 
buffer (pH 7.4). 
 
3.2.4. Mass Spectrometry. 
MS experiments were performed on a Synapt G2 ESI quadrupole-time-of-flight 
instrument (Waters, Milford, MA) operated in resolution mode. The capillary, sample cone, 
and extraction cone voltages were set at +2.8 kV, 25 V, and 4 V, respectively. MS/MS 
experiments were performed using collision-induced dissociation (CID) with argon as 
collision gas. Protein samples for bottom-up MS experiments were prepared by overnight 
digestion using trypsin (50:1 protein/trypsin) at 37 C, and subsequently analyzed by liquid 
chromatography – mass spectrometry (LC/MS) using a nanoACQUITY UPLC (Waters) 
with a C18 column. Samples for intact protein MS were prepared as 10 μM solutions in a 
50:50 solution of H2O:ACN with 0.1% formic acid, and directly infused at 5 μL min-1 using 
a syringe pump. For ion mobility-assisted top-down MS/MS experiments (top-down CID-
IM-MS), 16+ protein ions were quadrupole-selected prior to CID in the trap collision cell. 
The collision energy used was 23 V for all samples. Ion mobility spectrometry (IMS) 
separation of CID products was performed in N2 buffer gas at a wave velocity of 350 m s-
1 and wave height of 13 V. Simulated isotope distributions were generated using 
ProteinProspector (UCSF). All simulated spectra correspond to the ferric (Fe(III)) state of 
cyt c.  
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3.3. Results and Discussion 
3.3.1. Chloramine-T-induced Met80 Oxidation. 
The CT-cyt c used in this study was prepared using established procedures.37-38,47 
An initial characterization was conducted by subjecting unfractionated samples to a 
standard tryptic digestion/LC-MS/MS workflow. As expected, these assays revealed MetO 
formation (+16 Da) at Met80 and Met65, in line with earlier reports (Figure 3-2).17,37,46-47 
No other +16 Da modifications were detected. These observations appear to support the 
widely held belief that CT selectively oxidizes Met.17,48,50-51 However, from the data 
discussed below it will be seen that standard mapping experiments (such as those of Figure 
3-2) provide an incomplete view of the CT-induced oxidation events. 
 
 
3.3.2. SCX Fractionation and Optical Characterization. 
SCX elution profiles of CT-cyt c exhibited three major peaks (Figure 3-3A), 
consistent with previous observations.37-38,47-48 Close examination of the highest intensity 
region revealed the presence of two partially overlapping signals (around 23 mL, 
equivalent to “peak B” in ref. 37). In total, therefore, SCX revealed the existence of four 
chromatographically distinguishable CT-cyt c forms. We will refer to these fractions as I, 
II, III, and IV in the order of decreasing retention. Fraction I had the largest retention 
volume, i.e. it interacted most strongly with the stationary phase, implying the most highly 
cationic character. The SCX behavior of fraction I was indistinguishable from that of 
unmodified cyt c. Conversely, fraction IV showed the weakest interaction with the 
stationary phase, i.e. proteins in this fraction carried the least amount of positive charge. 
From the A280 values in the SCX chromatograms, the relative abundance of fractions IV, 
III, II, and I can be estimated to be roughly 10%, 35%, 35%, and 20%, respectively. For 
subsequent experiments we isolated thin slices out of the chromatograms for targeted 
experiments on each fraction (Figure 3-3A).  
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Figure 3-2. Tandem mass spectra of Met-containing tryptic peptides. In each panel, the top 
trace depicts the unmodified peptide, whereas the bottom trace depicts the MetO form. Top: 
peptide T15 (residues 80-86) reveals (+16 Da) at Met80. Bottom: peptide T13-14 (residues 
61-73), with MetO formation at Met65. These experiments were conducted on 
unfractionated samples. i.e. without prior SCX chromatography.  
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Figure 3-3. (A) Analysis of CT-cyt c by SCX chromatography. Four major species (I-IV) 
were discernible. Colored bars indicate collected fractions used for subsequent experiments. 
The elution volume of unmodified cyt c is indicated for comparison. (B) Peroxidase activity 
of CT-cyt c fractions measured in 100 μM H2O2. Error bars represent standard deviations 
of three independent experiments.  
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Optical spectra of the four CT-cyt c fractions were very similar to one another, but 
markedly different from those of unmodified cyt c (Figure 3-4). CT-cyt c showed a ~30% 
CD intensity loss at 222 nm, revealing some decrease of α-helicity upon oxidation.61 There 
was no concomitant increase in the random coil region (~200 nm), suggesting that CT-
induced modifications did not cause unfolding, but transitions to alternative folded 
structures.61 A blue shift of the UV-vis Soret band from 409 nm to ~405 nm indicated 
alterations in the heme environment. In addition, all CT-cyt c fractions exhibited loss of 
the 695 nm absorption band, signaling disruption of the Met80-Fe bond.62 
 
In summary, the spectroscopic data of Figure 3-4 indicate the formation of non-
native, structured conformers in the CT-treated samples. The CD spectra were similar to 
those of Lys-ligated alkaline cyt c.19,35-36 The blue-shifted Soret band is reminiscent of 
alkaline cyt c as well.34,38 Resonance Raman (RR) data in the literature showed Fraction I 
to be Lys-ligated, whereas the remaining fractions were reported to have an open (OH-
/H2O coordinated) distal site.37 All these observations support the view that CT-cyt c shares 
structural features with previously characterized alkaline cyt c conformers.19,34,36 Recent 
NMR and EPR work by Zhong et al. arrived at an analogous conclusion.38  
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Figure 3-4. Optical spectroscopy of CT-cyt c fractions. All data was compared against 
unmodified cyt c controls (dashed red trace) (A) Far-UV CD spectra. (B) Soret UV/vis to 
probe heme coordination environment. (C) A695 UV/vis band, characteristic of the Fe-
Met80 bond.  
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3.3.3. Peroxidase Activity of CT-cyt c Fractions. 
Despite their similar CD and UV-Vis spectroscopic properties (Figure 3-4), the four 
CT-cyt c fractions exhibited very different levels of peroxidase activity. Kinetic 
measurements were performed in the presence of 100 μM H2O2 (Figure 3-3B).59 Fraction 
I showed a relatively low activity; that of fraction II was twofold higher, and for fraction 
III an additional ~twofold increase was observed. Fractions III and IV had similar activities. 
For the low H2O2 concentration of Figure 3-3B, turnover was barely detectable for 
unmodified cyt c. This activity trend can be summarized as follows: unmodified cyt c < 
fraction I < fraction II < fraction III  fraction IV. The same trend was observed when the 
experiments were repeated at a higher H2O2 concentration of 500 μM, where even untreated 
cyt c showed non-zero activity (data not shown). 
 
A number of earlier studies implied that CT treatment of cyt c generates a 
homogeneous product that is oxidized only at Met80 and Met65.17,48,50 The data presented 
here demonstrate that this view is not correct. Instead, CT-cyt c is a mixture of at least four 
species that can be separated by SCX (Figure 3-3A) and that exhibit different peroxidase 
activities (Figure 3-3B). While SCX fractionation of CT-cyt c has been demonstrated 
previously,37-38,47-48 the chemical origin of this phenomenon and the associated activity 
differences remain unexplained. SCX separates proteins according to their cationic surface 
charge. CT-induced Met → MetO conversion does not directly alter the ionic nature of the 
protein (Figure 3-5). Conformational factors could, in principle, contribute to the SCX 
fractionation.48 However, the nearly indistinguishable CD and UV-Vis spectra point to 
similar overall structures for fractions I-IV (Figure 3-4), making conformational factors an 
unlikely culprit for the observed SCX behavior.  
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Figure 3-5. Structures of oxidation products of methionine (MetO, methionine sulfoxide) 
and lysine (LysCHO, aminoadipic semialdehyde). 
 
 
 
 
 
 
 
 
3.3.4. SCX Fractions Represent Specific Proteoforms. 
For uncovering the origin of the SCX properties and activity differences of fractions 
I-IV we applied a range of MS methods. As an initial step, intact protein mass spectra were 
acquired (Figure 3-6). At first glance, the mass distributions of the four fractions appear to 
be almost identical, reminiscent of the optical data in Figure 3-4. Each spectrum in Figure 
3-6 is dominated by two signals that are spaced +16 Da apart, as expected for MetO 
formation at Met80 and/or Met65. In addition, each fraction showed a low intensity signal 
close to the mass of unmodified cyt c. In Figure 3-6 these signals were annotated according 
to the number (0, 1, 2) of MetO formation events. This interpretation reflects the existing 
literature, which assumes that CT specifically targets Met80 and Met65 while leaving other 
residues unmodified.17,37-38,47-48,50-51  
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To test the viability of this simple MetO-centric interpretation we calculated 
theoretical isotope distributions for unmodified cyt c, a +16 Da variant (one MetO), and a 
+32 Da variant (two MetO). These theoretical distributions were superimposed on the 
experimental spectra (Figure 3-6, top row). Fraction I showed excellent agreement with the 
theoretical data. In contrast, fractions II, III, and IV exhibited gradually increasing mass 
defects, i.e. the measured peaks had a lower mass than expected. The magnitude of this 
discrepancy correlated with the SCX elution behavior: Fraction IV showed the largest 
discrepancy, while fraction I exhibited no discrepancy. The mismatch between 
experimental spectra and the theoretical “clean” +16 Da adducts implies that MetO 
formation is not the only type of covalent modification in fractions II-IV. Control 
experiments confirmed that mass discrepancies were already observable for unfractionated 
CT-cyt c, i.e. the observed effects were not an SCX-related artifact (Figure 3-7). 
 
 
 
 
Figure 3-6. Intact protein mass spectra of CT-cyt c fractions I-IV, focusing on the 16+ 
charge state, which yielded the highest signal intensity. Labels 0, 1, or 2 above peaks refer 
to the number of MetO sites (+16 Da). Top: Black lines/dots represent theoretical isotope 
distributions for MetO formation. Bottom: Magenta lines/dots represent theoretical isotope 
distributions for MetO formation plus one, two, or three LysCHO formation events (Lys 
carbonylation, -1 Da). Top and bottom panels in each column show the same experimental 
data with different isotope models.  
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The missing piece of the puzzle that explains the properties of CT-cyt c is Lys 
carbonylation (Figure 3-5). This reaction is known to be facilitated by metal centers (i.e. 
heme in cyt c).43 It involves a radical intermediate63 that gets converted to -hydroxylysine. 
Elimination of ammonia then produces LysCHO.64 Each LysCHO formation event is 
accompanied by a -1 Da shift.41,64 Compilations of known oxidative protein modifications 
reveals LysCHO formation to be the only process associated with a -1 Da shift.42-43 The 
direct MS-based detection of LysCHO sites will be discussed below. 
 
 
 
 
Figure 3-7. Intact protein ESI mass spectra of cyt c before (red) and after (magenta) CT 
treatment, but prior to SCX fractionation. Panels A and C depict the total charge state 
envelope, where panels B and D show a magnified view of the 16+ charge state. The data 
for unmodified cyt c are overlaid with a simulated isotopic distribution. The CT-cyt c mass 
spectrum is overlaid with simulated isotopic distributions for Met oxidation (+16 and +32 
Da, respectively). Major discrepancies are observable between simulated and experimental 
isotopic envelopes for CT-cyt c. These discrepancies are caused by the presence of 
LysCHO sites under the conditions of C/D.  
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Returning to Figure 3-6, revised modeling of the mass spectra to account for a 
combination of MetO (+16 Da) and LysCHO formation (-1 Da) resulted in excellent 
agreement between experimental and simulated spectra for all fractions (Figure 3-6, bottom 
row). The isotope models suggest that fractions I, II, III, and IV carry 0, 1, 2, and 3 LysCHO 
groups, respectively. These modifications are in addition to MetO formation at Met80 and 
Met65.17,37-38,47-48,50-51 
 
The different numbers of LysCHO groups provide an explanation for the SCX 
behavior of the four fractions. The SCX strategy used here separates proteins on the basis 
of their overall cationic charge; each LysCHO site reduces this charge by one unit.41-42,64 
In fraction I, the lack of Lys modifications causes the most positive surface charge, similar 
to that of unmodified cyt c (pI 9.6).65 Hence, fraction I (and unmodified cyt c) interact most 
tightly with the SCX column, resulting in the largest elution volume (Figure 3-3A). On the 
other extreme, fraction IV with its three LysCHO has lost three positive charges, causing 
those proteins to interact most weakly with the column. The behavior of fractions II and III 
falls in-between these two extremes. 
 
In summary, LysCHO formation accounts for the previously unexplained 
observation37-38,47-48 that CT-cyt c can be fractionated by SCX. LysCHO has been shown 
to play a role in the peroxidase activation of cyt c by H2O2.41 However, LysCHO formation 
in cyt c has not been reported for oxidizing agents other than H2O2. The number of LysCHO 
sites is the only detectable difference in the covalent structures of fractions I-IV, implying 
that LysCHO formation must be responsible for their different activities. Combining the 
information of Figure 3-3B and Figure 3-6, the peroxidase activity can be ranked according 
to the number of LysCHO: fraction I (0 LysCHO) < fraction II (1 LysCHO) < fraction III 
(2 LysCHO)  fraction IV (3 LysCHO).  
 
86 
 
3.3.5. Top-Down CID-IM-MS for Proteoform-Selective Analysis. 
Mapping of LysCHO sites poses significant analytical challenges.66 Typical 
bottom-up MS assays struggle with this task due to LysCHO-induced interference with 
tryptic cleavage and losses of ionization/fragmentation efficiency.42,67-68 Thus, it is not 
surprising that previous MS investigations failed to detect LysCHO in CT-cyt c.17-18,37-38,45-
48,50-51 To address these challenges we applied top-down MS/MS, i.e. gas phase 
fragmentation of undigested proteins.69 Initial attempts were unsuccessful due to the 
complexity of the fragment ion spectra. This problem was solved by incorporating ion 
mobility (IM) spectrometry to provide an additional separation dimension, thereby 
implementing a “top-down CID-IM-MS” workflow (Figure 3-8). Similar experiments have 
previously been applied to simple model systems,70-72 but this work marks the first time 
that such an approach was used for tracking unknown biologically relevant modifications. 
 
For validation, top-down CID-IM-MS was initially applied to peak 1 of fraction I 
(which is devoid of LysCHO) to examine the initial MetO formation event (Figure 3-9). 
All C-terminal fragments starting at y25 showed a +16 Da shift relative to unmodified cyt 
c. The y25 to y24 transition allowed the oxidation site to be identified as Met80 with single-
residue resolution. The presence of other oxidation sites in peak 1 (including Met65) could 
be ruled out. Measurements on peak 2 (+32 Da) verified Met80 and Met65 as the only two 
oxidation sites in fraction I (Figure 3-10). Taken together, these data imply that CT-induced 
MetO formation is a sequential process, with Met80 as the initial oxidation target whereas 
Met65 is affected at a later stage.  
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Figure 3-8. Principle of top-down CID-IM-MS experiments. (A) Fragmentation is initially 
achieved by precursor selection and CID in the trap collision cell of the Synapt G2, 
generating a complex mix of product ions. These fragment ions are then subjected to IMS, 
providing drift time information for each of the gas phase species, thereby adding a second 
dimension to the MS/MS spectrum (illustrated in panel B). (C) Representative example of 
peak assignments made possible by top-down CID-IM-MS of CT-cyt c. The initial MS/MS 
spectrum (top) shows signals that occupy the same m/z space; such the data cannot be 
interpreted. Using IMS, the complex multiplet can be separated into clean isotopic 
distributions: one corresponding to b458+, and another to y244+.  
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Figure 3-9. Top-down CID-IM-MS data that pinpoint MetO formation in fraction I. The 
sequence is shown along the top, with key fragments indicated. Bottom: Selected fragment 
ions from an unmodified control (red), and from peak 1 of fraction I (blue, see Figure 3-6). 
Lines/dots represent theoretical isotope distributions calculated for unmodified fragments 
(“no ox.”), or for MetO containing fragments. Met80 is the only covalent modification in 
peak 1 of fraction I.  
 
89 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-10. Representative CID-IM-MS fragment ions to determine the two sites of 
oxidation in peak 2 of fraction I (+32 Da). Top: Sequence of cyt c, with locations of 
diagnostic fragments labeled. Bottom: Representative fragment ions from an unmodified 
cyt c control (red) and fragment ions of peak 2 of fraction I (blue) overlaid with simulated 
isotopic envelopes, allowing mapping of the two +16 Da adducts to Met65 and Met80 with 
single-residue resolution for both.  
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Figure 3-11. Diagnostic top-down CID-IM-MS fragment ions of peak 1 for all CT-cyt c 
fractions, highlighting the fact that in all fractions Met80 gets oxidized first. In other words, 
the first MetO signal in all fractions does not originate from heterogeneous Met65/80 
oxidation. Each fragment ion is overlaid with a simulated isotopic envelope.  
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3.3.6. Mapping of LysCHO Sites. 
We next sought to identify the locations of LysCHO groups in fractions II, III, and 
IV by top-down CID-IM-MS. According to Figure 3-6, these fractions possess 1, 2, and 3 
carbonylation sites, respectively. LysCHO sites can be identified from -1 Da mass shifts of 
fragment ions. The experiments were facilitated by the fact that, fortuitously, peak 1 in all 
fractions corresponded exclusively to MetO formation at Met80 (Figure 3-11). Thus, 
LysCHO sites in the various fractions could be mapped via comparisons with fraction I 
fragments. By using this internal reference, we could unequivocally rule out calibration 
errors as an explanation for the observed -1 Da shifts. Our assignments were further 
verified by simulated isotope distributions that were overlaid onto the experimental spectra. 
 
Figure 3-12 reveals that for all fractions, N-terminal fragments up to b46, as well as 
C-terminal fragments up to y29 were indistinguishable from those of fraction I. This finding 
confines all LysCHO sites to residues 47-75 which comprise five out of the total 19 Lys 
residues. In fraction II, y-ions from y38 to y58 showed a -1 Da shift. The y38 to y29 transition 
narrowed down the location of this modification to 67YLENPKKYI75. Hence, the single 
LysCHO site in Fraction II is located on Lys72 or Lys73 (Figure 3-12, second row). 
 
Fraction III also showed a y38 to y29 -1 Da transition, implying one LysCHO 
modification on Lys72/73. An additional transition took place between y40 and y58, 
localizing the second LysCHO site to the region 49TDANKNKGITWKEETLM65. Thus, 
the second modification site in Fraction III is located on Lys53, Lys55, or Lys60 (Figure 
3-12, third row). 
 
Pinpointing the three LysCHO sites in Fraction IV was complicated by diminished 
fragmentation efficiencies that translated into low S/N ratios. This phenomenon likely 
reflects the loss of protonation sites after LysCHO formation, keeping in mind that the 
proximity to H+ sites favors b/y ion formation.73-75 y58 exhibited a mass shift of -3 Da 
(Figure 3-12, bottom row), confirming the presence of three LysCHO sites, as inferred 
from Figure 3-6. From the fragment ion mass shifts in Figure 3-12 (bottom row), the 
predominant modification pattern of fraction IV appears to be a single LysCHO in the 
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Lys53/55/60 range, plus two LysCHO at Lys72/73. However, we cannot rule out that the 
final LysCHO formation event also affects Lys53/55/60 to some extent. The similar 
peroxidase activities of fractions III and IV suggest that this third LysCHO is of minor 
functional importance. Experiments analogous to those of Figure 3-12 were conducted on 
peak 2 of each fraction, yielding LysCHO patterns similar to those of peak 1 (Figure 3-13). 
 
 
 
 
 
 
 
 
 
Figure 3-12. Selected top-down CID-IM-MS ions generated by fragmentation of peak 1 
from fractions I (blue), II (violet), III (orange), and IV (green). Each fragment ion is 
overlaid with its simulated isotopic envelope (lines/dots). Vertical dashed lines were 
included as visual aid to highlight LysCHO-related -1 Da mass shifts.  
 
93 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-13. Diagnostic CID-IM-MS fragment ions of peak 2 for all four CT-cyt c 
fractions. Each fragment ion is overlaid with a simulated isotopic envelope. Met oxidation 
for all fractions can be mapped to Met65 and Met80, each with single-residue resolution. 
The location of LysCHO sites is consistent with the assignments derived for peak 1 (Figure 
3-12), with some minor differences in fraction IV.  
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Figure 3-12 implies that CT-mediated LysCHO formation is a well-ordered process. 
Starting from LysCHO-free protein (fraction I), carbonylation initially affects Lys72/73 
(fraction II). The next carbonylation event takes place in the Lys53/55/60 region, 
generating fraction III. The final LysCHO site may affect Lys72/73 or Lys53/55/60. As 
noted above, MetO formation is also a sequential process, initially affecting Met80 and 
subsequently Met65. 
 
 
3.3.7. LC-MS/MS Peptide Mapping Revisited. 
The detection of LysCHO sites by top-down CID-IM-MS may seem at odds with 
previous studies on CT-cyt c that only found MetO formation.17,37-38,47 In intact protein MS 
data the small (-1 Da) mass shifts associated with LysCHO formation are easily overlooked, 
unless the spectra are carefully scrutinized via isotope modeling (Figure 3-6). Similarly, 
LysCHO detection by traditional tryptic digestion LC-MS/MS (e.g. Figure 3-2) is difficult 
due to reduced fragmentation resulting from charge site loss, and suppression of tryptic 
cleavage.42,73-75 These issues are exacerbated for the situation encountered here, where up 
to three LysCHO sites are confined to a fairly narrow sequence range (Lys53/55/60/72/73). 
 
Armed with the information from top-down CID-IM-MS, we revisited the tryptic 
digestion LC-MS/MS workflow with careful optimization of experimental parameters. 
Gratifyingly, we were able to confirm carbonylation of Lys72 in the missed-cleavage 
peptide T13-14 (residues 61-73, Figure 3-14). Consistent with the data reported above, this 
LysCHO peptide was found in fractions II-IV, but not in fraction I. No other LysCHO sites 
were detected by LC-MS/MS. Thus, the top-down CID-IM-MS workflow is superior for 
this type of application, as it allowed the detection of all three carbonylation sites (Figure 
3-12).  
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Figure 3-14. LC-MS/MS analysis of tryptic peptide T13-14 (61EETLMEYLENPKK73) in 
unfractionated CT-cyt c. Three LC separated variants were interrogated: unmodified (red), 
with Met65 oxidation (blue), and with both Met65 oxidation and Lys72 carbonylation 
(black). Top: fragment ion spectra. Bottom: Magnified views of representative fragment 
ions, highlighting +16 Da (MetO) and -1 Da (LysCHO) mass shifts. Ions denoted with an 
asterisk contain the LysCHO site. Simulated isotopic envelopes are shown as circles. Much 
lower collision energies (CE) were required for adequate fragmentation of the carbonylated 
peptide.  
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3.3.8. Mechanism of CT-induced Peroxidase Activation. 
The data of this work provide a clear view of the sequential CT-induced events that 
convert cyt c into an active peroxidase. This mechanism, summarized in Figure 3-15, is 
governed by the undisputed fact that peroxidase activity requires the distal coordination 
site to be accessible.14,16-17 Unmodified (native) cyt c has the lowest peroxidase-activity of 
all the forms studied here because its distal ligation site is blocked by Met80. Very slow 
substrate turnover under these conditions may take place as the result of conformational 
fluctuations52-53 that occasionally disrupt the Met80-Fe bond.40-41,76 
 
 
 
 
 
Figure 3-15. Model of CT-induced peroxidase activation of cyt c. SCX fractions I-IV 
exhibit different activity due to distal ligation changes. In unmodified cyt c the distal 
ligation site is blocked by Met80. In fraction I MetO formation has displaced Met80 from 
the heme iron, and distal ligation is provided by Lys72/73. In fraction II carbonylation of 
Lys72/73 causes a transition to distal ligation by Lys53/55. In fractions III and IV the heme 
has an open coordination site because carbonylation has abrogated the capability of 
Lys72/73 and Lys53/55 to act as distal ligands. Peroxidase activity increases from left to 
right, concomitant with increased accessibility of the distal ligation site. Dashed lines 
indicate Fe coordination bonds that can transiently open as a result of protein 
conformational fluctuations.  
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CT-induced oxidation of Met80 generates fraction I, an “alkaline” conformer where 
Lys72 or Lys73 has moved into the ligation site previously occupied by Met80. This 
ligation switch is supported by RR data37 as well as NMR and EPR experiments.38 While 
the enhanced peroxidase activity of alkaline Lys-Fe conformers is well documented,38 the 
origin of this effect is somewhat unclear because transient opening of the Lys-Fe contact 
takes place more slowly than for Met-Fe.34,77 Likely, the enhanced activity of fraction I is 
not caused by hexacoordinated Lys-Fe species per se, but by pentacoordinated structures 
that are part of the fraction I ensemble.14,38 RR spectra are consistent with this interpretation, 
suggesting the presence of ~15% pentacoordinated protein in the predominantly Lys-Fe 
coordinated fraction I (“peak A” in Figure S13 of ref. 37). Other factors may contribute to 
the peroxidase activity of Lys-ligated cyt c as well,41 one of these is the increased heme 
pocket volume which facilitates substrate access.19,77 
 
As the next step in Figure 3-15, carbonylation abrogates the iron ligating capability 
of Lys72/73, thereby generating fraction II. Fraction II still does not represent a genuine 
pentacoordinated conformer, evident from the fact that subsequent Lys53/55 carbonylation 
further enhances peroxidase activity (our MS data suggested the possible participation of 
Lys60, but we exclude this residue for reasons outlined below). Our data are thus consistent 
with a scenario where Lys53/55 participate in iron ligation in fraction II. However, these 
Lys53/55-Fe contacts must be quite labile, evident from the fact that fraction II has a higher 
activity than both fraction I and unmodified cyt c (Figure 3-3B). Carbonylation of Lys53/55 
subsequently produces fraction III which possesses a permanently open distal site and 
shows the highest peroxidase activity. RR data confirm that fraction III is pentacoordinated, 
as expected for a functional peroxidase.37 A final carbonylation event produces fraction IV 
which retains both an open distal site and peroxidase activity. 
 
The essential point in the activation cascade of Figure 3-15 is that CT-induced 
Met80 oxidation only results in a moderate level of peroxidase activity, because the distal 
site remains congested by Lys ligation. Subsequent CT-induced LysCHO formation frees 
up the distal site, thereby producing a genuine pentacoordinated heme. Previous work 
attributed the peroxidase activity of CT-cyt c exclusively to MetO formation,17-18,37-38,44-47 
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failing to recognize the occurrence and mechanistic significance of Lys carbonylation. Our 
data reveal that MetO formation only represents an initial step en route toward peroxidase-
activated CT-cyt c. Lys carbonylation represents a co-activator that boosts the activity by 
a factor of ~4 (fractions III/IV) relative to the MetO-only form (fraction I, see Figure 3-3). 
 
The model of Figure 3-15 provides a simple explanation for the correlation between 
the activity of the CT-cyt c fractions and their SCX behavior: both factors are directly tied 
to the number of LysCHO sites. When accounting for the SCX fractionation behavior, one 
has to remember that while the protein interacts with the anionic stationary phase, it may 
adopt structures and ligation scenarios that differ from the bulk solution conformations of 
Figure 3-15.78 
 
The ability of cyt c to adopt various distal ligation scenarios is consistent with the 
foldon model that dissects the protein into regions of different stability (Figure 3-16).52 The 
gray and red foldons (40-57 and 71-85 Ω loops, respectively) show the highest flexibility.52 
Not surprisingly, the alternative Fe ligands identified above are located in these two flexible 
regions, i.e. Lys72/73 (red) and Lys53/55 (gray). Opening of gray79 and red53 has 
previously been linked to alkaline conformers. The flexibility of gray and red also governs 
the CT-induced transitions outlined in Figure 3-15. In native cyt c the red foldon is 
anchored by the Met80-Fe linkage.52-53,79 Our data suggest that MetO formation sterically 
perturbs this (already labile)52 region, thereby triggering rearrangements that allow 
Lys72/73 to move into the distal site.53 The foldon hierarchy dictates that red can only open 
up when gray is already unfolded.52-53,79 Hence, after carbonylation of Lys72/73, the 
plasticity of the unfolded gray foldon will allow Lys53/55 to move into the vacated distal 
site. Our MS data suggest that Lys60 could also participate in Fe ligation, but its placement 
in the relatively rigid yellow foldon renders such a scenario less likely (Figure 3-16). 
 
Our data do not provide evidence for carbonylation of Lys79. In principle, this 
residue represents another possible ligand that might block access to the iron after Met80 
oxidation.38 However, evidence for such Lys79-Fe contacts comes primarily from work on 
K72A yeast iso-1 cyt c which has coordination propensities that are different from those of 
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the horse wild type studied here.38 Our findings suggest that Lys79-Fe contacts do not play 
a major role in Met80-oxidized horse cyt c, such that peroxidase activation is attainable 
without Lys79 carbonylation. 
 
 
 
 
 
 
 
Figure 3-16. Foldon structure of cyt c. Colors indicate the propensity to undergo transient 
unfolding: gray (least stable) > red > yellow > green > blue (most stable). Also shown are 
Lys side chains (magenta) that can act as distal Fe ligands during CT-induced peroxidase 
activation. Lys72/73 are in the “red” foldon (second-least stable, 71-85  loop). Lys53/55 
are in the “gray” foldon (least stable, 40-57  loop). On the basis of our MS results the 
participation of Lys60 (not shown) in heme ligation cannot be ruled out, but the positioning 
of Lys60 in the relatively rigid “yellow” foldon renders such a scenario less likely. N.B.: 
Various terms have been used for the gray foldon; these include “N”, “nested yellow”, “N-
yellow”, “infrared”, and “black”.52,53,79   
Lys73
Lys72
Lys55
Lys53
Met80 Fe
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3.4. Conclusions 
Our discovery of multiple, previously unreported carbonylation events in CT-cyt c 
calls into question the prevailing Met80-centric view of peroxidase activation, according 
to which oxidation of Met80 alone is sufficient for turning cyt c into a pentacoordinated 
peroxidase.17-18,37-38,44-45,47-48 The conclusions from a number of those reports have relied 
on the alleged fidelity of CT for specific Met oxidation. Several studies pooled the highest 
intensity region in the SCX chromatogram, assuming that samples obtained in this way 
represent the expected “clean” MetO species.37-38,47-48 Our data strongly suggest that such 
samples correspond to fractions II/III, with oxidation at Met80, Met65, and with LysCHO 
sites in the Lys72/73 and Lys53/55 range. Carbonylation of these samples enhances their 
peroxidase activity almost fourfold relative to fraction I, which represents the true MetO-
only species (Figure 3-3, Figure 3-6). It appears that past studies inadvertently studied 
carbonylated CT-cyt c proteoforms, misattributing some of the carbonylation-induced 
effects to MetO formation. 
 
Previous studies on CT-cyt c yielded conflicting results, according to whether the 
distal site is open,37 or occupied by Lys.38 The present work helps resolve these 
discrepancies. CT-cyt c comprises multiple species with different coordination patterns 
(Figure 3-15). Thus, any results will depend on the precise experimental conditions used 
for isolating protein from the CT-cyt c reaction mixture. 
 
Only four out of the 19 Lys residues in cyt c were identified as possible 
carbonylation sites. In native cyt c these four residues are relatively close to the distal face 
of the heme, which represents the site of peroxidase catalysis (Figure 3-1). Considering 
that all 19 Lys residues are solvent-exposed (Figure 3-17), the spatial selectivity of 
LysCHO formation rules out diffusion-mediated oxidation events, where modifications are 
governed by solvent accessibility.55 It instead appears that LysCHO formation is heme-
dependent.43,58 This line of thought bolsters our conclusions, as carbonylation of 
Lys53/55/72/73 confirms the capability of these residues to come in direct contact with the 
heme by serving as alternative Fe ligands (Figure 3-15). 
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There are certain parallels, but also differences between the CT-induced peroxidase 
activation of cyt c studied here, and the H2O2-induced activation that we explored earlier.41 
The initial transformation triggered by H2O2 is oxidation of Tyr67, while this residue 
remains unmodified during CT exposure. Peroxidase activation by both CT and H2O2 
involves sequential modifications and transiently populated alkaline conformers, 
ultimately producing a vacant distal site. One key difference is that CT-induced activation 
relies on MetO formation for disruption of the Met80-Fe bond (Figure 3-15). In contrast, 
H2O2 causes this bond to break as a result of Tyr67 oxidation, without Met80 oxidation. 
The reasons underlying the different initial reactivities of the two oxidants remain to be 
fully explored. Likely, H2O2 oxidation of Tyr67 proceeds with catalysis by the iron 
center,43 whereas CT can oxidize Met without heme involvement.51 A common feature of 
CT and H2O2-induced activation is LysCHO formation which prevents the distal site from 
being blocked by Lys side chains. It is likely that LysCHO formation plays a similar role 
for the conversion of cyt c into an apoptotic peroxidase under other conditions, e.g. after 
cardiolipin binding3,27-29 in vitro and in vivo. However, this hypothesis remains to be 
verified experimentally. 
 
 
Figure 3-17. Crystal structure of native cyt c (PDB: 1HRC) depicting all 19 Lys residues. 
Sites of Lys carbonylation are shown in green and labeled. All other Lys are shown in blue. 
(A) Front view. (B) Back view.  
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Chapter 4. Delineating Heme-Mediated versus Direct Protein 
Oxidation Pathways in Peroxidase-Activated Cytochrome c 
 
 
4.1. Introduction 
Covalent protein modifications by reactive oxygen species (ROS) impact numerous 
biological functions.1-6 The presence of ROS is an unavoidable consequence of aerobic 
cellular respiration.7 Protein oxidative modifications have been implicated in numerous 
aging and neurodegenerative pathologies.6,8-10 Protein oxidation is also involved in sensing 
and signaling,11-13 and it plays a major role for the efficacy and storage stability of protein 
therapeutics.14-16 Most protein oxidation events culminate in oxygen incorporation into side 
chains, e.g. Met → MetO (sulfoxide, +16 Da), Tyr → Tyr-OH (+16 Da), Lys-CH2-NH2 → 
Lys-CHO (carbonylation, -1 Da). Numerous additional oxidation pathways exist, and many 
residues can form various products (e.g., -2, +4, +16, +32, or +48 Da for Trp).17-21 In 
addition to oxidative modifications that occur within living cells, ROS can induce protein 
oxidation in vitro. Experimental strategies have been developed that use this approach for 
monitoring the solvent accessibility of individual side chains.20-26 In vitro oxidative 
modifications also provide the opportunity to investigate oxidation-induced changes in 
protein structure, dynamics, and function.5,13,25,27-30 
 
Regardless of context (i.e. in living cells or in the test tube), many aspects of protein 
oxidation are complex and incompletely understood. For example, side chain oxidation by 
∙OH can be a relatively simple process that starts with addition to a double bond or 
hydrogen abstraction, followed by quenching of the protein radical by an oxygen-
containing species.22 However, ∙OH can also act via mechanisms that are more convoluted, 
by producing secondary oxidants which then attack the protein.3,5,31-32 
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Some protein oxidation events are catalyzed by transition metals.18,33 Fenton-like 
reactions take place in the presence of peroxides, such as Fe(II) + H2O2 → Fe(III) + ∙OH + 
OH-. Subsequent metal reduction regenerates Fe(II) such that the process can continue, 
generating a steady supply of ∙OH that attack the protein.20,22,33 The peroxidase activity of 
some heme proteins represents another indirect metal-catalyzed process.34-36 In this case 
H2O2 reacts with Fe(III) heme to form “Compound I”, a Fe(IV)=O species with an adjacent 
radical. Hydrogen abstraction from R-H sites then regenerates Fe(III).37 The R∙ produced 
in this way undergo additional transformations which yield the final oxidation products. 
The aforementioned R-H can either be exogenous substrates or side chains in the vicinity 
of the heme; the latter scenario results in protein self-oxidation.5,38-41 
 
Many protein oxidation studies have focused on H2O2 and ∙OH,20,22 while other 
common oxidants have received less attention.2,42-44 Particular knowledge gaps persist for 
the widely used “mild” oxidant chloramine-T (CT, Figure 4-1).29-30,43-48 In aqueous solution 
CT transforms into other reactive species that include OCl-.44,46 The latter can cause side 
chain oxidation (e.g., Met + OCl- → MetO + Cl-), but alternative CT-induced protein 
oxidation pathways appear to exist.46 The exact nature of these pathways remains to be 
explored. 
 
 
 
 
 
 
 
Figure 4-1. Structure of the oxidant chloramine-T (N-chloro-4-toluosulfonamide), referred 
to as “CT” in this work.  
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Oxidative modifications of cytochrome c (cyt c, Figure 4-2) have attracted major 
attention over the past few years.25,29-30,41,44,47,49-53 Cyt c acts as an electron transporter in 
the respiratory chain by cycling between its Fe(II)/(III) heme oxidation states.54 In addition, 
cyt c can act as a peroxidase that catalyzes the oxidation of cardiolipin in mitochondria, a 
key step during apoptosis.53,55-58 Interestingly, the peroxidase activity of native cyt c is very 
low because the heme iron is fenced in by a 6-coordinate environment, being ligated by 
four pyrrole nitrogens, His18, and Met80. To become an active peroxidase cyt c must 
undergo a structural transition that severs the Fe-Met80 bond and generates 5-coordinate 
heme with an open distal site. This 5-coordinate form is catalytically active because it 
allows for Fe-peroxide interactions with subsequent formation of reactive Fe(IV)=O 
species.34,36,59 This peroxidase activation can be achieved by oxidative modifications of cyt 
c.27,29,44,47,52 The most common in vitro activation method is cyt c exposure to CT. The 
“CT-holo-cyt c” generated in this way represents an important model system for apoptosis 
research.29-30,44,47 
 
 
Figure 4-2. Crystal structure of equine holo-cyt c (PDB 1HRC).60 Met residues are 
depicted in orange. Sites of LysCHO formation are depicted in green. All remaining Lys 
are depicted in blue. The heme cofactor is depicted in black, and the heme iron is shown in 
red.  
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We recently conducted a detailed mass spectrometry (MS)-based characterization 
of CT-holo-cyt c, and we found it to be a mixture of structurally and functionally diverse 
proteoforms.27 In addition to MetO modifications at residues 80 and 65,29,44,47,52 CT-holo-
cyt c carries up to three carbonylated Lys. Both Met80 oxidation and Lys carbonylation are 
essential for peroxidase activation. The former ruptures the Fe-Met80 bond and generates 
the vacant coordination site required for catalysis, while the latter ensures that this site 
remains vacant by preventing Fe-Lys coordination.27 The presence of LysCHO in CT-holo-
cyt c and in other oxidation-activated forms of the protein had long been overlooked27-28 
but is now well accepted.25,41 A key finding of our previous work27 was that despite cyt c 
possessing 19 Lys that are equally solvent-accessible,60 only a small Lys cluster 
(53/55/72/73) was susceptible to LysCHO formation (Figure 4-2). The factors responsible 
for this unexpected specificity remain unexplored. 
 
Here we tackle the mechanism by which CT induces oxidative modifications in cyt 
c. Specifically, we investigated whether these transformations are mediated by the heme 
cofactor, keeping in mind the role of transition metal centers during the oxidation of other 
proteins.20,22,33 The strategy of our experiments is simple - we compared the effects of CT 
on holo-cyt c and apo-cyt c (the heme-free variant of the protein). Our work applied various 
MS tools. A particularly powerful approach is the fragmentation of intact proteins by top-
down MS/MS via collision-induced dissociation (CID), followed by ion mobility (IM) 
separation and mass analysis of fragment ions. This top-down CID-IM-MS method61-63 is 
superior to traditional bottom-up MS in cases where protein modifications such as LysCHO 
interfere with tryptic digestion, peptide ionization and fragmentation.27 Our experiments 
uncovered that Met → MetO conversion in cyt c can proceed in a heme-independent 
fashion. In contrast, LysCHO formation requires heme catalysis, a finding that explains the 
spatial selectivity of Lys carbonylation.  
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4.2. Methods 
4.2.1. Materials. 
Equine cyt c, CT, dithiothreitol (DTT), Girard’s reagent T (GRT, 
(carboxymethyl)trimethylammonium chloride hydrazide), Tris base (2-amino-2-
(hydroxymethyl)-1,3-propanediol), guanidinium chloride, and AgCl were supplied by 
MilliporeSigma (St. Louis, MO). Acetonitrile and ammonium acetate were supplied by 
Fisher (Nepean, ON). Potassium phosphate was from Caledon (Georgetown, ON). MS-
grade modified trypsin was obtained from Promega (Madison, WI). Centrifuge filters 
(Amicon Ultra 0.5, 10 kDa MWCO) were supplied by Millipore Sigma, and used following 
manufacturer instructions (15 min at 13,000 G; buffer exchange steps were performed 
using four cycles). Unless stated otherwise, reactions were performed at 22 ± 2 °C, and 
solutions contained 50 mM potassium phosphate (pH 7.4).  
 
4.2.2. Mass Spectrometry. 
MS experiments were conducted on a Waters SYNAPT G2-Si Q-TOF in positive 
ion mode. MS/MS experiments were performed using CID with Ar as collision gas. 
Samples were prepared as 5 M protein solutions in 50/50/0.1% H2O/acetonitrile/formic 
acid that were infused directly into the electrospray ionization (ESI) source of instrument 
at 5 L min-1. Top-down CID-IM-MS was performed as described27 using N2 as drift gas 
with trap collision energies between 22 and 25 V. The 16+ charge state served as precursor 
ion for top-down fragmentation. Bottom-up samples were digested overnight at 37 °C using 
a 50:1 protein:trypsin ratio. Tryptic peptides were separated on a Waters ACQUITY UPLC 
BEH C18 column (1.7 μm, 2.1 × 10 mm) with a H2O/acetonitrile gradient in the presence 
of 0.1% formic acid. MS/MS data were collected using data-dependent acquisition. Isotope 
distributions were modeled using Protein Prospector (http://prospector.ucsf.edu). 
 
4.2.3. Heme Removal: Preparation of apoSS-cyt c. 
Heme in cyt c is covalently bound by thioether linkages to Cys14 and Cys17.60 
Heme removal was performed as described64 with some modifications. Cys-S-heme bonds 
were initially replaced with Cys-S-Ag bonds. For this purpose, 200 μL glacial acetic acid 
 
112 
 
were added to 1.8 mL of an aqueous solution of 400 μM cyt c and 25 mM AgCl, followed 
by incubation at 40 °C in the dark for 4 h and centrifugation at 13,000 G for 5 minutes. The 
supernatant was buffer exchanged into 100 mM acetic acid, yielding apo-cyt c carrying up 
to three silver ions (Ag-apo-cyt c, Figure 4-3B). For Ag removal, 100 μL Ag-apo-cyt c was 
added to 900 μL of 50 mM pH 5 ammonium acetate containing 6 M guanidinium chloride 
and 1 M DTT, followed by incubation for 3 h. Samples were then buffer exchanged into 
50 mM pH 5 ammonium acetate, yielding apo-cyt c (ε280 = 10.9 mM-1 cm-1)65 with both 
Cys14 and Cys17 in the thiol form. The absence of heme was confirmed by MS (Figure 
4-3C) and UV-Vis (Figure 4-4). The apo-cyt c generated in this way underwent a mass 
shift of -2 Da during storage (Figure 4-5A) that was reversible upon addition of DTT 
(Figure 4-6). This behavior indicates -SS- bond formation between Cys14 and Cys17. To 
obtain homogeneous stable heme-free samples we deliberately promoted formation of this 
-SS- bond by storing 10 μM apo-cyt c for 24 h at 22 C, followed by overnight incubation 
at 4 °C. The disulfide-containing protein generated in this way is referred to apoSS-cyt c. 
Top-down CID-IM-MS confirmed the presence of a disulfide between Cys14 and Cys17 
in apoSS-cyt c, while simultaneously verifying the absence of other covalent modifications 
(Figure 4-5B, C). 
 
4.2.4. CT-induced Oxidation and GRT Labeling. 
50 μM apoSS-cyt c or holo-cyt c were incubated in 2.5 mM CT/50 mM pH 8.4 Tris 
buffer for 3 h.66-67 The reaction was halted by buffer exchange into 50 mM pH 5 ammonium 
acetate, yielding CT-apoSS-cyt c and CT-holo cyt c. We also prepared apoSS-cyt c samples 
that were less oxidized by using 0.5 mM instead of 2.5 mM CT (CTlow-apoSS-cyt c). 
Oxidation experiments in the presence of microperoxidase 11 (MP11) were performed 
using the same procedures, except that 50 μM MP11 was added to the CT/protein reaction 
mixture. Covalent tagging of reactive carbonyl groups was performed using GRT15 by 
incubating 10 μM protein (CT-treated or unoxidized controls) with 80 mM GRT in 50 mM 
pH 5 ammonium acetate for 3 h. Excess GRT was removed by buffer exchange into 50 
mM pH 5 ammonium acetate.  
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Figure 4-3. Left: Intact protein ESI mass spectra of different cyt c forms. (A) Holo-cyt c 
(unmodified control), (B) Ag-cyt c, (C) apo-cyt c. Far right: Cartoon representation of each 
form. 
 
 
Figure 4-4. UV/Vis absorption spectra of cyt c before and after heme removal: holo-cyt c 
(red), apo-cyt c (blue).   
H18
C17
C14
M80
Fe
C17
C14
HS
HS
C17
C14
 
114 
 
 
Figure 4-5. (A) Mass spectra of apo-cyt c highlighting a disulfide-induced mass shift after 
storage. (B) ApoSS-cyt c sequence; selected top-down fragmentation sites are indicated. (C) 
Representative top-down CID-IM-MS fragment ions from apo-cyt c (top) and apoSS-cyt c 
(bottom). All spectra are overlaid with their modeled isotope distributions (black dots and 
lines). 
 
 
 
Figure 4-6. Mass spectrum (charge state 16+) of apoSS-cyt c (A) before DTT treatment and 
(B) following DTT treatment. The vertical dashed line is included as a visual aid. Following 
DTT treatment, the -2 Da mass shift is lost, and the original (free -SH) mass is recovered.  
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4.3. Results and Discussion 
For probing the role of heme during CT-induced cyt c oxidation we compared the 
behavior of the native protein and its heme-free counterpart. To assist readers, we briefly 
recapitulate the sample types that were used here, and that were prepared as described 
above: (i) Holo-cyt c is the native protein, possessing a covalently attached heme. (ii) 
ApoSS-cyt c is devoid of heme, and its Cys14 and Cys17 side chains are linked by a -SS- 
bond (Figure 4-5). (iii) CT-holo-cyt c refers to holo-cyt c after oxidation by CT, comprising 
various proteoforms with MetO formation at residues 80 and 65, and one or more LysCHO 
in the Lys53/55/72/73 range.27 (iv) CT-apoSS-cyt c refers to apoSS-cyt c after oxidation by 
CT, under conditions identical to those used for CT-holo-cyt c. (v) CTlow-apoSS-cyt c was 
exposed to a five-fold lower CT concentration than CT-apoSS-cyt c. Oxidative 
modifications in CT-apoSS-cyt c and CTlow-apoSS-cyt c have not been characterized 
previously. 
 
 
4.3.1. Effects of CT-Induced Oxidation. 
Intact protein mass spectra of the aforementioned protein species are depicted in 
Figure 4-7. CT-holo-cyt c and CT-apoSS-cyt c both showed oxidative modifications, with 
~16 Da peak progressions that represent the hallmark of +nO incorporation. Similar 
patterns have previously been reported for many other oxidized proteins.5,20,22 The 
spectrum of CT-holo-cyt c had its maximum at +2 O (Figure 4-7B), while that of CT-apoSS-
cyt c was dominated by signals around +4 O (Figure 4-7E). This observation reveals that 
heme removal renders cyt c more susceptible to oxidation by CT. Comparable oxidation 
levels to holo-cyt c could be achieved only when incubating apoSS-cyt c samples in five-
fold less CT (Figure 4-7D).  
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Figure 4-7. Intact protein mass spectra (charge state 16+) depicting the effects of cyt c 
oxidation by CT. (A) holo-cyt c (untreated control). (B) CT-holo-cyt c. (C) apoSS-cyt c. (D) 
CTlow-apoSS-cyt c. (E) CT-apoSS-cyt c. Black solid lines and dots are modeled isotope 
envelopes. Vertical dashed lines mark the positions expected for “clean” +nO 
modifications; experimentally observed deviations from these “clean” positions are 
indicated in pink.  
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Close inspection of Figure 4-7 reveals deviations from “clean” +nO behavior. In 
CT-holo-cyt c, the signals were shifted by -2 Da due to LysCHO formation (Figure 4-7B).27 
CT-apoSS-cyt c showed a similar negative shift (Figure 4-7E). This -2 Da shift was absent 
for CTlow-apoSS-cyt c (Figure 4-7D). While the -2 Da shift in Figure 4-7E seems to suggest 
the presence of LysCHO in CT-apoSS-cyt c, the data discussed below reveal that it has a 
different origin. 
 
It may seem counterintuitive that heme removal enhances the oxidation 
susceptibility of cyt c, considering the capability of metal centers to catalyze 
oxidation.20,22,33-36 However, metal catalysis is not the only factor that is relevant in this 
context. CD spectroscopy revealed that heme removal causes cyt c unfolding (Figure 4-8), 
confirming earlier reports that the protein structural integrity is contingent on heme.64 The 
enhanced oxidation susceptibility of apoSS-cyt c is attributable to the fact that unfolding 
renders previously buried side chains sterically accessible to CT. This interpretation is in 
line with studies on other proteins where unfolding was found to enhance modifications by 
water-soluble labeling agents.20,22,68-69 
 
 
Figure 4-8. Far-UV CD spectra of holo-cyt c (red) and apoSS-cyt c (blue). The minimum 
close to 200 nm for apoSS-cyt c reveals that heme removal causes the protein to adopt an 
extensively unfolded conformation.  
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4.3.2. Oxidation Site Mapping. 
We performed top-down CID-IM-MS to identify the modifications in CT-apoSS-
cyt c and CTlow-apoSS-cyt c (Figure 4-9). Data for CT-holo-cyt c were included for 
comparison (Figure 4-10), although an in-depth analysis of this species has already been 
reported.27 All top-down experiments were performed by fragmenting [M + “2 O”] ions. 
The quotation marks indicate the presence of additional -2 Da modifications in CT-holo- 
cyt c and CT-apoSS-cyt c that cause deviations from “clean” +2 O (+32 Da) Da mass shifts. 
Fragment spectra of all three CT-oxidized forms shared a y24 to [y25 + O] transition, as well 
as a [y39 + O] to [y40 + 2 O] transition (Figure 4-9 and Figure 4-10). This pattern confirms 
MetO formation at both Met80 and Met65 for all three species (CT-holo-, CT-apoSS-, and 
CTlow-apoSS-cyt c). These observations demonstrate that CT-induced MetO formation can 
take place without heme catalysis. This conclusion is in line with the fact that Met is one 
of the most easily oxidizable residues,20 that is known to be capable of forming MetO 
without metal catalysis.45,70-71 
 
A more intriguing question is the nature of the -2 Da shift in CT-apoSS-cyt c (Figure 
4-7E). As noted, -2 Da shifts in CT-holo-cyt c are caused by LysCHO formation in the 
range of Lys53/55/72/73.27 Does CT-apoSS-cyt c contain these modifications as well? The 
top-down data of Figure 4-9 localize the -2 Da modification in CT-apoSS-cyt c between 
residues 49 and 64, ruling out modifications at Lys72/73. The 49-64 range comprises 
Lys53/55/60 such that LysCHO formation could, in principle, be a possible explanation of 
the observed -2 Da shift. However, subsequent experiments demonstrate that CT-apoSS-cyt 
c is free of LysCHO.  
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Figure 4-9. Top-down CID-IM-MS analysis of CT-apoSS-cyt c. (A) protein sequence with 
selected fragmentation sites. The remaining three panels show partial fragment spectra. 
The two modified Met residues are highlighted in color, along with the sequence range that 
harbors an additional -2 Da modification. (B) Top: apoSS-cyt c (untreated control). Center: 
CTlow-apoSS-cyt c. Bottom: CT-apoSS-cyt c. Each spectrum is overlaid with its theoretical 
isotopic envelope.  
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Figure 4-10. Top-down CID-IM-MS analysis of CT-holo-cyt c. (A) protein sequence with 
selected fragmentation sites. The two modified Met residues (MetO sites) are highlighted 
in color. (B) Representative top-down CID-IM-MS fragment ions. Top: holo-cyt c 
(untreated control). Bottom: CT-holo-cyt c. Each spectrum is overlaid with its 
corresponding theoretical isotopic envelope (solid circles and black lines).  
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4.3.3. Confirming LysCHO Sites by GRT Labeling. 
GRT is a hydrazide compound that selectively reacts with ketones and aldehydes 
(such as LysCHO). Other modified side chains that might potentially be present (such as 
Tyr dimers, -2 Da)5 do not react with GRT.15,72-73 GRT labeling of CT-holo-cyt c produced 
satellite peaks corresponding to +1 GRT and +2 GRT, confirming the presence of two 
LysCHO sites that are responsible for the -2 Da mass shift of CT-holo-cyt c (Figure 
4-11B).27 Top-down CID-IM-MS of the most intense GRT adduct confirmed GRT labeling 
at Lys72/73 (Figure 4-12), in agreement with earlier work.27 
 
Figure 4-11. Intact protein mass spectra (charge state 16+) depicting the effects of GRT 
labeling. (A) CT-holo-cyt c prior to GRT labeling. (B) CT-holo-cyt c after GRT labeling. 
(C) CT-apoSS-cyt c prior to GRT labeling (D) CT-apoSS-cyt c after GRT labeling. Dashed 
vertical lines mark expected position of GRT-modified species. The first peak of each 
distribution is overlaid with its theoretical isotopic envelope.  
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Figure 4-12. Top-down CID-IM-MS analysis of GRT-labeled CT-holo-cyt c. (A) protein 
sequence with selected fragmentation sites. The two modified Lys residues are highlighted 
in colour. (B) Representative top-down CID-IM-MS fragment ions. Top: CT-holo-cyt c 
(no GRT control). Bottom: GRT-labeled CT-holo-cyt c, using the [M + 2 O + 1 LysCHO 
+ 1 GRT] peak as precursor. Each spectrum is overlaid with its corresponding theoretical 
isotopic envelope (solid circles and black lines).  
G D V E K G K K I F V Q K C A Q C H T V E K G G K H K T G P
N L H G L F G R K T G Q A P G F T Y T D A N K N K G I T W K
E E T L M E Y L E N P K K Y I P G T K M I F A G I K K K T E 
R E D L I A Y L K K A T N E
b46
1
31
61
91
y29y40
y56
A
B
 
123 
 
Given the much higher overall oxidation propensity of CT-apoSS-cyt c relative to 
CT-holo-cyt c (Figure 4-7), one might expect correspondingly more LysCHO sites (and 
thus more extensive GRT labeling). Surprisingly, CT-apoSS-cyt c was completely 
unreactive with GRT (Figure 4-11D). The same was observed for CTlow-apoSS-cyt c (Figure 
4-13). This lack of GRT reactivity reveals that CT is incapable of forming LysCHO in 
apoSS-cyt c. It can be concluded that LysCHO is not a general byproduct of CT-induced 
oxidation. Instead, Figure 4-11 strongly suggests that CT can induce LysCHO formation 
in cyt c only in the presence of heme. 
 
As LysCHO is absent in CT-apoSS-cyt c, the -2 Da shift in this protein form must 
arise from another modification. As noted earlier, top-down CID-IM-MS localized the -2 
Da shift to 49TDANKNKGITWKEETL64 (Figure 4-9). Scenarios such as ThrCH-OH → 
ThrC=O (-2 Da) can be excluded by the lack of GRT labeling in CT-apoSS-cyt c.20-21 Trp 
is the residue with the highest intrinsic oxidation propensity in the 49-64 range.20 Studies 
on other proteins showed that Trp yields various oxidation products, including -2 Da 
species.74 Using bottom-up MS/MS we were able to detect low-level Trp59 oxidation in 
CT-apoSS-cyt c (Figure 4-14). Unfortunately, we could not unequivocally attribute the -2 
Da mass shift to Trp59 in these experiments. Based on the arguments outlined above, Trp59 
nonetheless represents the most likely culprit for the -2 Da modification in CT-apoSS-cyt c. 
The unfolded structure of apoSS-cyt c increases the reactivity of Trp59,64 while in native 
holo-cyt c this residue is buried.60 This enhanced solvent exposure renders Trp59 more 
prone to oxidation in apoSS-cyt c.20,22,68-69  
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Figure 4-13. Intact protein mass spectra (charge state 16+) of CTlow-apoSS-cyt c, depicting 
a lack of GRT labeling due to the absence of LysCHO. (A) Spectrum before GRT exposure. 
(B) Spectrum after GRT exposure. The vertical line in panel B marks position where the 
GRT-labeled protein would be expected. The asterisks mark background contaminant 
signals. 
 
 
 
 
Figure 4-14. Bottom-up MS/MS of the tryptic peptide 56GITWK60 depicting oxidation of 
Trp59 (+14 Da) in CT-apoSS-cyt c. This peptide was not detected in any other sample.  
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4.3.4. Confirming Heme Catalysis Using MP11. 
The absence of LysCHO in CT-apoSS-cyt c strongly suggests that this type of 
modification can form only with heme catalysis. However, skeptics might point out that 
other differences between holo-cyt c and apoSS-cyt c could play a role as well. For example, 
it could be possible that the absence of LysCHO in CT-apoSS-cyt c is somehow related to 
the unfolded structure of this protein form (Figure 4-8). To conclusively test the role of 
heme, we produced CT-apoSS-cyt c in the presence of exogenous heme in the form of 
MP11. MP11 is a heme-containing cyt c fragment (residues 11-21). The Fe(III) in MP11 
is coordinated by His18 while the distal site remains open, allowing MP11 to catalyze a 
range of oxidation reactions.75-76 The covalent thioether linkages in MP11 preclude 
reconstitution of native holo-cyt c upon mixing with apoSS-cyt c, allowing us to delineate 
the effects of protein conformation vs. heme involvement on the protein oxidation 
behavior. 
 
The presence of MP11 during CT-apoSS-cyt c formation profoundly impacted the 
mass spectra (Figure 4-15). The most obvious effect was a dramatic shift toward lower 
charge states (i.e. from maxima around 16+/17+ down to 11+/12+) which indicates the loss 
of numerous charge-bearing sites (i.e., Lys-CH2-NH3+ → LysCHO).77 Abundant LysCHO 
formation is also apparent from the mass distribution (Figure 4-15F) which shifted by ca. 
-10 Da, corresponding to ca. 10 LysCHO. We attempted to use GRT labeling of MP11/CT-
apoSS-cyt c for confirming the presence of LysCHO; however, those experiments yielded 
spectra with low S/N that were difficult to analyze (not shown). Keeping in mind that apoSS-
cyt c is normally unreactive with GRT due to the absence of LysCHO (Figure 4-11F, Figure 
4-13B), it is likely that this low S/N arises from over-labeling of MP11/CT-apoSS-cyt c by 
GRT. To nonetheless obtain direct confirmation of LysCHO, we performed MP11 
experiments under the milder oxidation conditions of CTlow-apoSS-cyt c. These experiments 
yielded the expected GRT-labeled products, confirming the ability of MP11 to induce the 
conversion of Lys to LysCHO (Figure 4-16B,C). 
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In summary, our data reveal that LysCHO formation by CT is a heme-dependent 
process. This finding explains the unusual selectivity of LysCHO formation in CT-holo-
cyt c which affects only 4 out of the 19 Lys side chains.27 All of the affected residues 
(Lys53/55/72/73) are in close spatial proximity to the reactive (distal) heme face,27 
rendering them poised for heme-catalyzed oxidation (Figure 4-2). Other Lys are not 
targeted because they lack the spatial requirements for interaction with the endogenous 
heme. This spatial selectivity is reminiscent of metal-catalyzed oxidation events in other 
proteins.33 In contrast, the exposure of apoSS-cyt c to freely diffusible heme (in the form of 
MP11) removes this geometric requirement, allowing heme to freely sample positions 
close to any of the 19 Lys and thus resulting in large-scale, non-selective, “global” LysCHO 
formation (Figure 4-15F). This non-selectivity is also apparent from the multiple fragment 
ion populations seen after top-down CID-IM-MS fragmentation of GRT-labeled 
MP11/CTlow-apoSS-cyt c (Figure 4-16D). 
 
 
 
Figure 4-15. Intact protein mass spectra, illustrating the effects of MP11 during preparation 
of CT-apoSS-cyt c. (A/D) apoSS-cyt c with MP11 but without CT; (B/E) with CT but without 
MP11; (C/F) with CT and with MP11. (A-C) depict full charge state envelopes. (D-F) show 
a magnified view of the 12+ charge state. Vertical lines are present as a visual aid.  
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Figure 4-16. Mass spectra depicting GRT labeling experiments of MP11/CTlow-apoSS-cyt 
c. Intact protein mass spectra (charge state 16+) are depicted in panels A-C. (A) 
MP11/CTlow-apoSS-cyt c without GRT, and (B) with GRT. (C) Magnified view of (B) 
highlighting the GRT-labeled protein, overlaid with its simulated isotope distribution. (D) 
Representative top-down CID-IM-MS fragment ions, highlighting the presence of multiple 
ion populations in GRT-labeled MP11/CTlow-apoSS-cyt c. Top: CTlow-apossCyt c (no GRT 
treatment). Bottom: GRT-labeled MP11/CTlow-apossCyt c. The b46 and y57/56 ions shown in 
panel D cover mutually exclusive regions of the protein. If the precursor ion were 
homogeneously modified at a single site, then only one of these complementary fragment 
ions could contain the modification. The observation of a GRT-containing peak in both 
fragment ions demonstrates that there is more than one GRT site.  
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4.4. Conclusions 
CT-holo-cyt c represents an important model system that mimics the state produced 
in vivo when cells embark on their path towards apoptosis.27,29-30,44,47 CT-induced oxidation 
of cyt c produces a 5-coordinate Fe(III) that is required for peroxidase activity. These 
modifications were identified as MetO at residue 80, as well as LysCHO formation in the 
Lys53/55/72/73 range.27 The current work provides new insights into the chemistry 
underlying these transformations. In agreement with previous studies45,70-71 we found that 
MetO-formation in cyt c can proceed without heme. The key finding of this study is that 
CT-induced LysCHO formation is heme-catalyzed, and that it only takes place in the direct 
vicinity of heme. The heme can be endogenous as in the case of holo-cyt c, or it can be 
exogenous as in our MP11 experiments. 
 
The role of metal catalysis during CT-induced oxidation of small organic substrates 
has been examined previously, e.g. for Os(VIII) oxide and In(III) triflate.46,78 However, 
there seems to be no prior work related to the reactivity of CT in the presence of Fe or 
heme. We consider it most likely that the heme-catalyzed Lys oxidation seen here involves 
OCl-. It is known that CT produces OCl-,44,46 and it is also known that OCl- interacts with 
heme to generate Compound I and related Fe(IV)=O species.79-81 The formation of such 
species in our MP11 experiments is favored by the fact that the distal heme face in MP11 
is freely accessible.75-76 In the case of holo-cyt c, OCl--Fe interactions require opening of 
the heme crevice. Such opening events are facilitated by the high flexibility of the 71-85 Ω 
loop that covers the distal heme face in native cyt c.82-83 Disruption of the Fe-Met80 contact 
via MetO formation further enhances the tendency of this Ω loop to sample oxidant-
accessible conformation.28,84-85  
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It is tempting to speculate on the broader implications of heme-catalyzed LysCHO 
formation, relative to other oxidation pathways. Compound I-dependent oxidation involves 
the abstraction of H atoms by radical oxygen species.34 Analogous H abstraction takes 
place during other oxidation methods, e.g. Fenton chemistry33 or direct exposure to ∙OH.20 
Likely, all of these methods generate similar (if not identical) types of oxidation products. 
It is therefore surprising that LysCHO formation has been observed after Fenton reactions86 
and other metal-catalyzed processes,18 but not after direct ∙OH exposure.20-21 One possible 
explanation is that LysCHO tends to go undetected in conventional bottom-up LC-MS/MS 
workflows because LysCHO sites interfere with tryptic digestion and collision-induced 
dissociation of peptides.27 However, further studies are necessary to explore this 
possibility. 
 
From a bioanalytical perspective, this work demonstrates that top-down MS is 
highly suitable for interrogating heterogeneous oxidative modifications, including 
LysCHO sites which are difficult to track when using traditional bottom-up workflows.27 
Future top-down investigations will be aided by continuing advancements in 
instrumentation that enable high-resolution analyses of proteins with ever-increasing size 
and complexity.87-89 It is hoped that this work will stimulate further top-down MS studies 
in the exciting field of protein oxidation.  
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Chapter 5. Probing the Effects of Heterogeneous Oxidative 
Modifications on the Stability of Cytochrome c in Solution and 
in the Gas Phase 
 
 
5.1. Introduction 
Atomically resolved structural data for proteins in solution or in the solid state can 
be obtained by X-ray crystallography, NMR spectroscopy and cryo-electron microscopy. 
Mass spectrometry (MS) and ion mobility spectrometry (IMS) offer complementary 
avenues. Prerequisite for the application of these vacuum techniques is the capability to 
generate intact gaseous protein ions.1 Electrospray ionization (ESI)2 and matrix-assisted 
laser desorption/ionization (MALDI)3 represent key techniques for this purpose, but new 
ionization methods continue to emerge.4-8 Particularly interesting is recent work by 
Trimpin et al.8 which demonstrated that gaseous protein ions can be generated without the 
aid of lasers, heat, or voltages. 
 
The amino acids in natively folded proteins are closely packed and engaged in H-
bonds, salt bridges, van der Waals interactions, and hydrophobic contacts.9 Covalent 
modifications can upset this interaction network, destabilize the native state, and render 
proteins non-functional.10 One avenue to introduce such modifications involves reactive 
oxygen species, such as O2−, HO2∙, H2O2, and ∙OH.11-14 Methionine conversion to sulfoxide 
(MetO) is particularly common,15-18 but oxidation can also affect many other residues.19-20 
The accumulation of oxidized proteins plays a key role for aging-related pathologies21 such 
as Alzheimer’s and other neurodegenerative diseases.22-23 In addition, oxidation 
compromises the efficacy of protein therapeutics.16,18,24 Understanding oxidation-related 
effects on protein structure and stability, therefore, is an important goal with far-reaching 
repercussions.  
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Oxidation-induced stability changes in solution can be studied using thermal15,18,25-
26 or chemical27-28 unfolding experiments. These studies involve protein exposure to heat 
or chemical denaturants. Optical tools can then be used to probe unfolding profiles, e.g. 
circular dichroism (CD) spectroscopy at 222 nm which reports on -helicity.29 The melting 
temperature TM marks the unfolding midpoint and is a measure of protein stability.9,30-31 
Oxidative modifications usually destabilize proteins in solution, inducing shifts to lower 
TM.15,18,25-28 
 
In addition to the aforementioned solution studies, there is considerable interest in 
examining proteins in a solvent-free environment. “Native” ESI can generate gaseous 
biomolecular ions that retain solution-like structures and interactions.7,32-36 Somewhat 
analogous to thermal unfolding in solution,15,18,25-26,30 these gaseous protein ions can be 
subjected to collisional heating, causing them to undergo collision-induced unfolding 
(CIU). The structural changes triggered in this way are detectable by IMS.37-38 
 
It is an interesting question whether gas phase stabilities correlate with the protein 
behavior in solution.39-40 A number of studies indicate that this indeed appears to be the 
case. For example, enzyme-inhibitor binding stabilities in solution were consistent with 
trends seen in collision-induced dissociation (CID) studies,41 ligand-induced stabilization 
effects were mirrored in the gas phase,42 and CIU energetics were shown to be correlated 
with solution structures.38 Correlation between solution and gas phase behavior was also 
demonstrated in surface-induced dissociation (SID) experiments on multi-protein 
assemblies,36 and blackbody infrared dissociation (BIRD) studies on protein-lipid 
complexes.43 On the other hand, the absence of solvent can have profound effects on inter- 
and intramolecular contacts.44 Hydrophobic interactions are weakened,45 while 
electrostatic contacts are strengthened in the absence of water.46 These factors can lead to 
disparities between solution and gas phase stabilities.46 Overall, much remains to be learned 
about the relationship between protein stability in vitro and in vacuo. Particular knowledge 
gaps persist when it comes to the question how oxidative modifications affect the stability 
of gaseous proteins.  
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Oxidative modifications of the heme protein cytochrome c (cyt c) have attracted a 
lot of attention in recent years.47-56 The canonical function of cyt c is to shuttle electrons in 
the respiratory chain.57 In addition, cyt c acts as a peroxidase, i.e. an enzyme that catalyzes 
the oxidation of organic substrates by H2O2.58 Cyt c-catalyzed oxidation of cardiolipin in 
mitochondria plays a key role during apoptosis.59-62 The peroxidase activity of native cyt c 
is low. It is only after specific oxidation events that the protein becomes fully active.47-54,63-
64 This gain of function contrasts the aforementioned scenarios where oxidation events 
interfere with protein activity. 
 
The most common method for producing peroxidase-active cyt c in vitro is by 
exposure to chloramine-T (CT),47,51,53-54 a mild oxidant that releases OCl-.65 We recently 
conducted a detailed MS characterization of CT-treated cyt c (CT-cyt c).63 The protein was 
found to be highly heterogeneous, with MetO formation at zero, one, or two methionines 
(Met80 and Met65). In addition, CT-cyt c showed Lys carbonylation in the range of 
Lys72/73 and Lys53/55 (Figure 5-1).63 Lys carbonylation to aminoadipic semialdehyde is 
associated with M = -1 Da (LysCH2-NH2 → LysCHO).66-67 This type of modification is 
easily missed because of its small mass shift, loss of a charged site, and abrogation of 
tryptic cleavage. In particular, the presence of LysCHO in CT-cyt c had been overlooked 
until recently.63 Both MetO and LysCHO are well-known markers for oxidative damage in 
environmentally stressed proteins and protein therapeutics.67-68 Therefore, CT-cyt c 
represents as a convenient model system for probing the effects of these modifications on 
protein structure and stability. 
 
Here we characterize the effects of oxidative modifications in CT-cyt c on the 
stability of the protein in solution and in the gas phase. We find that although the solution 
stability of the protein is reduced after oxidation, gas phase data show an increase in 
stability. We conclude that the solution properties of oxidatively modified proteins are not 
necessarily reflected in their CIU behavior.  
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Figure 5-1. Crystal structure of horse cyt c (PDB 1HRC). (A) Front view with highlighted 
side chains that are oxidized after CT exposure: Met (red), and Lys (green). The heme iron 
is shown in orange. (B) Side view with highlighted Met residues and selected aromatic side 
chains. 
 
 
 
 
 
 
 
 
5.2. Materials and Methods 
5.2.1. Materials. 
Cyt c (equine heart), CT (N-chloro-4-toluosulfonamide), and Tris base (2-amino-
2-(hydroxymethyl)-1,3-propanediol) were supplied by MilliporeSigma (St. Louis, MO). 
All other chemicals were supplied by Fisher Scientific (Nepean, ON) or Caledon 
Laboratories (Georgetown, ON). Centrifuge filters (Amicon Ultra 0.5, 10 kDa MWCO) 
were supplied by Millipore Sigma, and used according to manufacturer instructions (15 
min at 13,000 G).  
A
M80
M65
K73
K72
K55
K53
B
M65
M80
F82
Y67
W59
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5.2.2. Protein Oxidation. 
CT-cyt c was prepared as described63, with minor modifications. 500 μM cyt c was 
incubated with 2.5 mM CT in 50 mM Tris (pH 8.4) for 60 min at 22 C. Oxidation was 
quenched by five serial exchanges into 10 mM ammonium acetate using Amicon filters. 
The resulting proteoform mixture was fractionated using a 5 mL SCX HiTrap SP cartridge 
(GE Healthcare). Samples were eluted using a zero to 500 mM ammonium acetate gradient 
(pH 9). 
 
5.2.3. Thermal Unfolding. 
Solution phase unfolding was monitored by CD spectroscopy at 222 nm using a J-
810 spectropolarimeter (JASCO, Easton, MD). Samples were prepared as 10 μM protein 
in 50 mM potassium phosphate buffer (pH 7.4). Heating was performed from 20 to 100 °C 
at a rate of 1 °C min-1. The melting temperature (TM) and enthalpy of unfolding (ΔH) were 
extracted by fitting the CD222 profiles using30 
 
 
 
𝐶𝐷222 =
(𝑦𝑁 + 𝑚𝑁𝑇) + (𝑦𝑈 + 𝑚𝑈𝑇)exp (−∆𝐺/𝑅𝑇)
1 + exp (−∆𝐺/𝑅𝑇)
 
 
(5.1) 
 
where T is the temperature in Kelvin and G = H(1 – T/TM), while (yN + mNT) and (yU + 
mUT) represent the pre- and post-transition baselines, respectively. The fraction of unfolded 
protein in solution (Fu_sol) was calculated as69 
 
 
 
𝐹𝑢_𝑠𝑜𝑙 =
exp (−∆𝐺/𝑅𝑇)
1 + exp (−∆𝐺/𝑅𝑇)
 
 
(5.2) 
 
There was no evidence of aggregation, as seen from the absence of precipitated protein in 
the heated samples. 
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5.2.4. Mass Spectrometry. 
MS experiments were performed on a Waters SYNAPT G2-Si instrument in 
positive ion mode (Waters, Milford, MA). Samples were prepared as 10 μM protein in 
either 10 mM ammonium acetate for native ESI, or 50/50/0.1 H2O/methanol/formic acid 
for denaturing conditions, and infused at 5 μL min-1. Travelling wave IMS experiments 
were performed in sensitivity mode with N2 as buffer gas. Instrument parameters were 
tuned to maintain minimal ion activation prior to deliberate activation for CIU. CIU was 
performed by varying the trap collision energy, with Ar as collision gas. IMS profiles of 
8+ ions were extracted using TWIMextract.70 IMS drift times were converted into effective 
helium collision cross sections ().71 CIU curves were expressed as fraction unfolded in 
vacuum (Fu_vac), defined as 
 
 
𝐹𝑢_𝑣𝑎𝑐 =
〈𝛺〉 − 〈𝛺𝑁〉
〈𝛺𝑈〉 − 〈𝛺𝑁〉
 
 
(5.3) 
 
where <Ω> is the average Ω at a given trap collision energy. <ΩN> and <ΩU> are the 
average Ω values measured for minimum (1 V) and maximum collisional excitation (20 
V), respectively. All CIU experiments were performed in triplicate, with independent  
calibrations for each replicate. Error bars represent standard deviations. Simulated isotope 
distributions of Fe(III) cyt c were generated using the UCSF ProteinProspector web server.  
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5.3. Results and Discussion 
5.3.1. Chromatographic Separation of Proteoforms. 
Exposure of cyt c to CT produces a mix of oxidation products that are modified at 
Met and Lys side chains.63 The complexity of these CT-cyt c samples can be alleviated by 
using strong cation exchange (SCX) chromatography. Under the conditions used here, 
three major SCX fractions were obtained (I, II, and III in Figure 5-2A). The SCX retention 
time of fraction I (where no Lys is oxidized) was virtually identical to that of unmodified 
control samples which had not been exposed to CT. 
 
A cursory glance at the mass distributions of the three CT-cyt c fractions suggests 
that they are quite similar to one another. Each fraction showed three dominant signals, 
corresponding to 0, 1, and 2 MetO modifications (approximately +0, +16, +32 Da, Figure 
5-2B-D). The 1 MetO species were previously shown to be oxidized at Met80, while the 2 
MetO proteoforms are modified at Met80 and Met65.63 However, close examination and 
comparison with modeled isotope distributions reveals additional mass shifts of -2, -1, and 
-0 Da for fractions III, II, and I. These negative shifts are attributable to the presence of 2, 
1, and 0 LysCHO sites. Proteoforms with a -1 Da shift are carbonylated at Lys72/73, while 
-2 Da species are additionally modified at Lys53/55.63 The progressive loss of positive 
charge for these proteoforms is consistent with their SCX retention behavior, keeping in 
mind that SCX separates proteins based on their cationic character in solution. Specifically, 
fraction III which has lost the most charge due to two Lys+ → LysCHO conversion events 
was most weakly retained (Figure 5-2A). 
 
The observation that all three fractions share virtually the same MetO oxidation 
pattern (Figure 5-2B-D) indicates that Met oxidation and Lys carbonylation occur 
independently of one another during cyt c exposure to CT. The inability of SCX to separate 
proteoforms with different MetO content reflects the fact that this type of modification does 
not affect the protein charge.  
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Figure 5-2. SCX fractionation of CT-cyt c. (A) Chromatogram after CT exposure; three 
major fractions I, II, and III are highlighted. (B-D) Mass spectra of the 16+ charge state for 
each fraction (colored lines), overlaid with isotopic models (black solid lines and dots). (E) 
Unmodified cyt c. The number of MetO and LysCHO modifications for each peak is 
indicated. Vertical dashed lines were included as a visual aid.  
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In summary, the CT-cyt c preparations examined here represent a mix of 
proteoforms that contain 0, 1, or 2 MetO sites, as well as 0, 1, or 2 LysCHO modifications. 
SCX allows separation into three fractions that are pure with respect to LysCHO content, 
but heterogeneous in the number of MetO sites. The separation of CT-cyt c into three 
fractions facilitates the subsequent experiments, compared to investigations on unseparated 
samples. 
 
 
5.3.2. Stability of CT-cyt c in Solution. 
Unfolding experiments were performed to establish how CT-induced oxidative 
modifications affect the stability of cyt c in solution (Figure 5-3). Instead of using chemical 
denaturation27-28 we chose thermal unfolding assays15,18,25-26 to allow a direct comparison 
with gas phase CIU experiments (discussed below), keeping in mind that both techniques 
probe the protein response to heat. The thermodynamic parameters measured for 
unmodified cyt c were TM = 86.8 ± 0.2 °C and ΔH = 493 ± 20 kJ mol-1. The former agrees 
with literature data within 1 °C.72 Previous work reported a somewhat lower ΔH (400 kJ 
mol-1)73 but that earlier study used acidic solutions, while our experiments were performed 
at pH 7.4. Compared to the unmodified controls, all three CT-cyt c fractions showed a 
substantial decrease in both TM (ca. 5 °C) and ΔH (ca. 50%), revealing that CT-induced 
oxidative modifications reduce the stability of the protein in solution (Table 5-1). The 
stability reduction seen here for CT-cyt c is reminiscent of data reported previously for 
other oxidatively modified proteins.15,18,25-28 
 
Interestingly, stability differences between the individual oxidized fractions I, II, 
and III were small, evident from their almost superimposable unfolding profiles (Figure 
5-3). As discussed above, the three fractions only differ in the number of modified Lys 
residues (0, 1, 2 LysCHO for fractions I, II, III), while they share very similar MetO 
compositions. From this, one can conclude that LysCHO formation does not significantly 
affect the protein stability in solution, consistent with the location of these modifications 
on side chains that protrude into the solvent (Figure 5-1A).  
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Table 5-1. Thermodynamic parameters derived from the thermal 
unfolding experiments of Figure 5-3. 
  TM (°C)  ΔH (kJ mol-1) 
Unmodified Control  86.8 ± 0.2 493 ± 20 
Fraction I 81.6 ± 0.1 238 ± 4 
Fraction II 82.7 ± 0.1  276 ± 6 
Fraction III 82.5 ± 0.2  269 ± 8 
 
 
 
 
 
 
 
Figure 5-3. Solution phase thermal unfolding of cyt c monitored by CD spectroscopy at 
222 nm. Data are shown for unmodified control protein, and for fractions I, II, III of CT-
cyt c. (A) Experimental data points (circles) are overlaid with fits (solid lines) according to 
Equation (5.1). TM and ΔH values derived from these fits are compiled in Table 1. (B) 
Fraction of unfolded protein in solution (Fu_sol) calculated according to Equation (5.2).  
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Instead, the major stability difference between unmodified cyt c and CT-cyt c are 
attributable to MetO formation. Oxidation of the deeply buried Met80 is expected to be 
particularly disruptive because it ruptures the distal Fe-sulfur bond and interferes with side 
chain packing in the protein core.74 Met65 modifications likely affect the protein stability 
to a lesser extent, because this residue is located close to the protein surface without any 
critical side chain contacts (Figure 5-1A). 
 
 
5.3.3. ESI Charge States of CT-cyt c. 
Because the formation of each LysCHO is concomitant with the loss of a basic 
(protonatable) site, one might expect that the ESI charge state distribution of [M + zH]z+ 
ions could be affected by LysCHO formation. However, native ESI mass spectra of 
unmodified controls and fractions I-III were very similar to one another, with charge state 
distributions dominated by 8+/7+ ions. In contrast, spectra acquired under denaturing 
conditions exhibited slight shifts to lower charge states, from maxima of 17+/16+ for 
unmodified cyt c and fraction I, down to 16+/15+ for fraction III (Figure 5-4). 
 
Native ESI proceeds according to the charged residue model (CRM), where protein 
ions are released upon droplet evaporation to dryness. Charge states generated under these 
conditions are close to those of protein-sized water droplets at the Rayleigh limit (zR  7.9 
for cyt c).75-77 Thus, CRM charge states of globular proteins are governed by their surface 
area, rather than the number of basic sites.78 The fact that native ESI generates very similar 
charge state distributions for unmodified and CT-cyt c indicates that the covalent 
modifications encountered here do not dramatically alter the overall compactness of the 
protein. This view is consistent with native ESI  values which are very similar for all 
proteoforms (see below). 
 
The situation is different under denaturing ESI conditions, where protein ions likely 
form according to the chain ejection mechanism (CEM).77 The CEM proceeds with gradual 
ejection of extended protein chains from the droplet surface, in concert with the 
equilibration of mobile H+ between the droplet and its protein appendage. Any factor that 
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decreases the effective basicity of the protein will compromise the capability of the chain 
to compete for H+ during ejection. The slight shift to lower charge states seen for fraction 
III under denaturing ESI conditions therefore likely reflects the loss of basic sites due to 
conversion of two Lys to LysCHO (Figure 5-4). In summary, the ESI charge state 
distributions of the various proteoforms are consistent with current views of the ESI 
process under native and denaturing conditions.75-77 
 
 
 
 
 
 
 
Figure 5-4. Mass spectra of unmodified cyt c and the three CT-cyt c fractions. Data were 
acquired under native ESI conditions (left) and under denaturing conditions (right).  
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5.3.4. Native ESI Gas Phase Conformations of CT-cyt c. 
We initially probed the conformations of unmodified 8+ cyt c ions and fractions I-
III with minimum collisional excitation (collision energy 1 V) in an effort to preserve 
solution-like structures in the gas phase.7,32-36 Figure 5-5A-D displays the resulting IMS 
data in a MetO-averaged fashion. The unmodified control protein displayed a single 
dominant feature centered at ~1350 Å2, consistent with previous reports.79-82 Virtually the 
same IMS behavior was seen for fractions I-III (Figure 5-5A-D, Table 5-2). These native 
ESI data reaffirm that CT-induced oxidation does not induce large-scale global alterations 
of the protein structure, although minor perturbations are known to take place.54,63 Our IMS 
data are quite different from those of a recent report55 where it was concluded that oxidative 
modifications cause a significant compaction of cyt c. The IMS data of ref. 55 showed 
multiple peaks for both unmodified and oxidized cyt c, suggesting that the ions had 
undergone partial CIU. In contrast, our native ESI-IMS data (and previous studies79-82) are 
dominated by single IMS features, presumably corresponding to solution-like 
conformations that were not significantly affected by collisional heating. Unfortunately, 
the IMS data of ref. 55 were not Ω-calibrated, rendering a direct comparison with our 
results difficult. 
 
 
5.3.5. Gas Phase Stability of CT-cyt c. 
While the aforementioned IMS experiments avoided collisional excitation, we will 
now discuss the CIU behavior of the various CT-cyt c proteoforms to assess their gas phase 
stabilities. Similar to unfolding in solution, the extent of structural perturbation in these 
CIU experiments can be expressed as a fraction unfolded (Fu_vac, Equation (5.3)). IMS/MS 
is capable of tracking the IMS profiles of each individual MetO and LysCHO species (see 
below). In contrast, the solution unfolding experiments of Figure 5-3 could only probe the 
behavior of fractions I-III in a MetO-averaged fashion. To allow a direct comparison with 
those solution data, we initially compiled MetO-averaged CIU data (Figure 5-5).  
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Figure 5-5. CIU of unmodified cyt c and CT-cyt c fractions I-III for 8+ ions generated by 
native ESI. The data shown here represent an average of all the MetO isoforms in each 
fraction. (A-P) IMS profiles acquired at different trap collision energy (Trap CE) values, 
as indicated along the left. Arrows indicate notable features that are discussed in the text. 
(Q) CIU unfolding profiles for each type of sample, expressed as Fu_vac.  
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Table 5-2. Collision cross sections () measured for unmodified cyt c and CT-cyt c 
under various conditions. All values in Å2 are for 8+ ions generated by native ESI. 
  Unmod control 1347 ± 10 M
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  Fraction II 1337 ± 5 
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1 1720 ± 3 1724 ± 4 1726 ± 4 
2 1724 ± 2 1725 ± 2 1724 ± 3 
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Raising the collision energy from 1 V to 20 V resulted in significant gas phase 
unfolding for all 8+ species, transforming the “native” (~1350 Å2) IMS distributions into 
unimodal profiles centered at ~1730 Å2 (Figure 5-5, Table 5-2). Although the <Ω> values 
of CT-cyt c at the lowest and highest collision energies were very similar to the unmodified 
protein, there were clear differences in the intermediate energy regime. At 7 V all of the 
IMS profiles had maxima around 1400 Å2. In addition, the unmodified control exhibited a 
major feature at ~1700 Å2, which is close to the fully unfolded protein (marked by the red 
arrow in Figure 5-5E). This unfolded feature was also seen for fractions I-III, but at much 
lower intensities (Figure 5-5F-H). Upon raising the collision energy to 9V the IMS 
distribution of the unmodified control was completely dominated by this ~1700 Å2 feature 
(Figure 5-5I), while more compact conformers (around 1500 Å2) persisted for fractions I-
III (see arrows in Figure 5-5J-L). No major differences are seen when comparing the CIU 
data for fractions I-III among each other. 
 
Overall, our data reveal that the unmodified control protein is more susceptible to 
CIU than fractions I-III. This effect is also apparent from the Fu_vac profiles (Figure 5-5Q) 
which have a midpoint at 0.5 V – 1 V lower collision energies for unmodified cyt c than 
for fraction I-III. Based on these Fu_vac profiles alone it might be difficult to discern the 
differences between unmodified cyt c and fractions I-III; however, the dissimilarities seen 
in the IMS distribution for intermediate collision energies are striking (Figure 5-5E-L). The 
observed oxidation-induced stabilization of cyt c in the gas phase (Figure 5-5) contrasts 
the destabilization observed in solution (Figure 5-3).  
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5.3.6. Proteoform-Resolved CIU Analysis. 
More detailed insights into the role of each modification can be obtained by 
extracting IMS profiles of individual proteoforms. The three MetO variants are separable 
by their mass differences (+0, +16, +32 Da), while the LysCHO variants (0, -1, -2 Da) can 
be resolved using SCX fractionation. To facilitate the following discussion, we will identify 
proteoforms as KmMn, where m and n are the number of LysCHO and MetO, respectively. 
For example, K0M0 represents unmodified cyt c, while K2M1 refers to the proteoform 
containing 2 LysCHO and 1 MetO. 
 
To investigate the effects of MetO in the absence of LysCHO modifications we 
probed the K0Mn series (n = 0, 1, 2, Figure 5-6). At intermediate collision energies, both 
K0M1 and K0M2 had structures that were significantly more compact than for K0M0, 
evident from the features highlighted with arrows in Figure 5-6D-I. Also, the midpoints of 
the K0M1 and K0M2 CIU profiles are ~1 V higher than that of K0M0, while the former 
two are virtually superimposable (Figure 5-6M). From these data it can be concluded that 
oxidation of Met80 (in K0M1) enhances the gas phase stability of the protein, while the 
additional oxidation of Met65 (in K0M2) has no discernible effect. 
 
A similar analysis was conducted to investigate the effects of LysCHO 
modifications by focusing on the KmM1 series (m = 0, 1, 2, Figure 5-7). The IMS 
distributions (Figure 5-7A-L) and CIU profiles (Figure 5-7M) for these three species were 
very similar across all collision energies, suggesting that LysCHO formation only has 
minor effects on the gas phase stability of cyt c. The last aspect is consistent with the 
behavior in solution (Figure 5-3), where the number of LysCHO also has a negligible effect 
on stability. This is in stark contrast to MetO formation at residue 80 which greatly affects 
the properties of cyt c, giving rise to opposing stability trends in solution and in the gas 
phase.  
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Figure 5-6. CIU of K0Mn proteoforms (zero LysCHO; n = 0, 1, 2 MetO) for 8+ ions 
generated by native ESI. (A-L) IMS profiles for each sample at different trap collision 
energies. (M) CIU unfolding profiles.  
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Figure 5-7. CIU of KmM1 proteoforms (m = 0, 1, 2 LysCHO; 1 MetO) for 8+ ions 
generated by native ESI. (A-L) IMS profiles for each sample at different trap collision 
energies. (M) CIU unfolding profiles.  
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5.4. Conclusions 
Our results reveal that CT-induced oxidation affects the cyt c stability in solution 
and in the gas phase quite differently. In solution, CT-cyt c has a melting point that is ~5 
C lower than that of unmodified cyt c, implying large-scale destabilization. In the gas 
phase, oxidative modifications cause a small but distinct stabilization, evident from a ~1 V 
shift to higher CIU voltages. Our results indicate that both of these effects can be attributed 
largely to MetO formation of Met80, a residue that is deeply buried and represents the 
distal heme ligand in the native state.74 The effects of other CT-induced oxidative 
modifications on protein stability are less pronounced (MetO formation at Met65, and 
LysCHO formation at Lys72/73 and Lys53/55). The lack of major changes following 
modification of these other sites is consistent with their solvent-exposed locations which 
allow covalent modifications to be accommodated without disrupting the side chain 
packing in the core (Figure 5-1A). 
 
The observation that Met80 oxidation reduces the protein stability in solution is 
consistent with a wide range of observations on other oxidatively modified proteins, 
reflecting the fact that oxidation events usually perturb steric interactions, polarity, 
hydrophobicity, etc.15,18,25-28 In cyt c the conversion of Met80 to MetO additionally ruptures 
the distal Met-Fe bond.47,51,53-54 It seems surprising, therefore, that this modification would 
render the protein more resilient to CIU in the gas phase. One possible explanation is the 
formation of new bonds after conversion of Met80 to MetO. Recent work has shown that 
the partially positive sulfur atom in MetO can noncovalently bind to the partially negative 
 electron clouds of aromatic rings.83 Several aromatic residues are relatively close to 
Met80 (Trp59, Tyr67, Phe82, Figure 5-1B), and thus it seems conceivable that the 
enhanced gas phase stability could be rooted in newly formed contacts of MetO with one 
of these sites. Interestingly, computer simulations predict that such MetO-aromatic 
contacts will be disfavored in water.84 This could explain our observation of MetO-induced 
destabilization in solution vs. stabilization in the gas phase. 
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It is also somewhat surprising that Lys carbonylation does not have a destabilizing 
effect in the gas phase, keeping in mind the role of strengthened electrostatic contacts in 
vacuo and the likely involvement of Lys+ in salt bridges at the protein surface.46 It is 
possible that the loss of basic sites due to LysCHO formation is compensated by other 
factors, such as dipole interactions of -CHO sites with positively charged moieties on the 
protein surface. 
 
Overall, the results of this work highlight the fact that protein stability trends 
observed in solution are not always mirrored by the corresponding gaseous ions, consistent 
with the findings of several previous studies.44-46 Investigating the origin of these different 
trends offers exciting opportunities to better understand the complex interplay of 
electrostatic and other noncovalent contacts in native and covalently modified proteins. It 
is hoped that future comparative solution/gas phase investigations will provide further 
insights into the molecular foundation of oxidation-induced alterations on protein function 
and stability.  
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Chapter 6. Summary and Future Work 
 
 
6.1. Summary 
The peroxidase activity of cyt c plays a critical role in triggering programmed cell 
death (apoptosis). However, the hexacoordinated heme cofactor present in native cyt c 
should render this activity impossible. Despite the central biological importance of this 
peroxidase function, the molecular mechanisms underlying this structural paradox are 
poorly understood. The work detailed in this dissertation fills this knowledge gap by 
deciphering the central role of protein oxidative modifications and their associated 
structural changes in activating the peroxidase function of cyt c. 
 
In Chapter 2, the critical role of in situ structural changes in triggering the 
peroxidase activity of cyt c was uncovered. These changes were triggered by multiple 
oxidative modifications induced by H2O2. Using top-down MS, we established that the 
initial oxidative modifications occur sequentially, yielding a stepwise model to peroxidase 
activation. A key modification in this capacity was the oxidation of Lys into its 
corresponding aldehyde (LysCHO). 
 
In Chapter 3, we extensively characterized the oxidized cyt c proteoforms produced 
by treatment with CT. We discovered that this purportedly well-characterized model 
system represents a mixture of structurally and functionally distinct proteoforms that differ 
primarily by the extent of LysCHO formation at key sites. 
 
In Chapter 4, we established the causal factors underlying the observed specificity 
in the formation of LysCHO and other oxidative modifications by comparing the oxidation 
behaviour of cyt c with its heme-free counterpart (apo-cyt c). These experiments revealed 
that LysCHO is formed by heme-mediated catalysis, while other modifications (e.g. MetO) 
proceed via direct interaction with the oxidant. 
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In Chapter 5, we utilized CT-treated cyt c as a model system to test the compatibility 
of protein stability measurements in the gas phase to their counterparts in solution. Unlike 
many other reported systems, for which good qualitative agreement was observed, we 
discovered that oxidized cyt c shows opposite stability trends in the gas phase and in 
solution. 
 
 
6.2. Future Work 
6.2.1. Peroxidase Activation In Vivo 
The work described in Chapter 2 and Chapter 3 constitutes in vitro approaches to 
studying the peroxidase activation of cyt c that were designed to emulate oxidative 
conditions present in vivo, such as those at the onset of apoptosis and other biological 
states.1,2 While some previous studies have attempted to directly map how cyt c may be 
modified by ROS in vivo, such reports remain scarce, and structural details remain lacking.3 
To the best of our knowledge, there does not yet exist any systematic reports detailing the 
types of oxidized proteoforms cyt c may form in vivo. 
 
It is interesting to note that studies of cyt c and apoptosis in a cellular context 
commonly employ protein immunoblotting (i.e. Western blotting) using anti-cyt c 
antibodies.4–6 It is unclear whether these antibodies possess sufficient specificity to 
differentiate unmodified cyt c from its oxidized variants. The presence of oxidized cyt c 
proteoforms in vivo may explain some unusual observations in the literature. For example, 
Ott and coworkers reported that cyt c in mitochondria exists in two “pools”, which differ 
by the strength of their interaction to the inner mitochondrial membrane.7 The first pool 
could be dislodged by increasing ionic strength, while the second pool required both 
increasing ionic strength and addition of an oxidizing agent. While the authors attributed 
this behaviour to the existence of two distinct cyt c conformers, it seems plausible that the 
first “pool” may instead correspond to oxidatively modified cyt c. The MS-based 
experiments described in this dissertation would be amenable to analyze these potential 
protein variants.  
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6.2.2. Cyt c / Cardiolipin Interactions 
Interactions between cyt c and the membrane lipid cardiolipin (CL) play a key role 
in the apoptosis-triggering function of cyt c.8–11 CL is thought to be the primary target of 
the peroxidase activity of cyt c that initiates apoptosis. Although a large body of work has 
attempted to uncover how cyt c interacts with CL,12–18 the precise nature of 1) how cyt c 
binds to CL, and 2) how (and if) the structure of cyt c changes in response to CL binding 
remains contentious. A major hurdle to the structural elucidation of the cyt c / CL complex 
is that the “complex” is likely a mixture of multiple conformations and/or binding modes, 
rendering spectroscopic characterization difficult.13 MS-based experiments, particularly 
HDX-MS, may be an alternative technique to study these conformational ensembles.19 The 
multiple protein conformations may be discernable via HDX-MS by the appearance of 
multiple isotopic envelopes following deuterium labeling. Moreover, as ligand-binding 
commonly manifests itself as a decrease in the rate of exchange, HDX-MS could also 
elucidate the locations of the CL binding site(s). 
 
Given our elucidation of an H2O2-induced pathway of peroxidase activation1 
(Chapter 2), an alternative question could be: how does CL binding affect the oxidative 
modifications induced by H2O2? Recent work by Barayeu and coworkers using bottom-up 
MS found that cyt c is extensively oxidatively modified by H2O2 in the presence of CL.20 
However, the direct link between these reported modifications and their effects on 
peroxidase activity currently remains unknown. Top-down MS of the cyt c/CL/H2O2 
system would provide insight on the interplay between these factors. 
 
 
6.2.3. Oxidation Mapping in Other Systems 
The work described in Chapter 4 describes the causal factors behind the origin of 
specific oxidative modification products such as LysCHO. Due to the difficulty of 
detecting LysCHO by the standard bottom-up MS approach, it seems possible that 
LysCHO is a general, underreported protein oxidative modification that is also produced 
by other oxidation sources (e.g. direct ∙OH attack). However, this remains to be verified 
experimentally. Experiments described in this dissertation (e.g. GRT labeling) would aid 
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in the detection of such species. The verification of LysCHO formation is of particular 
importance for techniques that require accurate quantitation of all oxidative modification 
products, such as hydroxyl radical-based protein footprinting.21,22 
 
Bottom-up MS is currently the de facto standard for identifying protein oxidative 
modifications.21–23 However, the current dissertation demonstrates the feasibility of top-
down MS approaches for this task, even for complex mixtures of oxidized proteoforms. 
The primary advantage of top-down MS is the ability to detect modifications at the 
proteoform level, allowing any correlations between the various modifications to be 
directly observed. We anticipate that this will be particularly impactful for studying 
oxidative damage pathways in proteins.24–28 Top-down MS would allow these pathways to 
be directly mapped via the observed distributions of oxidized proteoforms. Moreover, 
information such as the temporal relationships between the pathways (or even of specific 
modifications along each pathway) can in theory be readily obtained. 
 
Another application of top-down MS that we envision is for time-resolved 
hydroxyl-radical based protein footprinting. Techniques such as Fast Photochemical 
Oxidation of Proteins (FPOP) rely on rapid labeling (ideally in the µs regime) to footprint 
rapid kinetic processes such as protein folding.29–31 Two prominent challenges in these 
experiments are 1) controlling the labeling timescales such that only the transient species 
of interest is being footprinted, and 2) ensuring the protein is only labeled once to minimize 
label-induced structural perturbations (“single-shot” labeling). While much work has been 
invested at addressing these challenges (e.g. radical scavengers, rapid-mixing, single-pulse 
lasers), their success has been controversial.32 Top-down MS has the capacity to resolve 
proteoforms with different extents of oxidative labeling by their different masses. Using 
top-down MS, single-shot conditions could in theory be guaranteed, irrespective of labeling 
kinetics, by selecting only the singly-labeled proteoforms for analysis. The top-down MS 
work described in this dissertation set the stage for such proteoform-resolved oxidation 
experiments.  
 
165 
 
6.3. References 
(1)  Yin, V.; Shaw, G. S.; Konermann, L. J. Am. Chem. Soc. 2017, 139 (44), 15701–
15709. 
(2)  Yin, V.; Mian, S. H.; Konermann, L. Chem. Sci. 2019, 10 (8), 2349–2359. 
(3)  Birk, A. V.; Chao, W. M.; Liu, S. Y.; Soong, Y.; Szeto, H. H. Biochim. Biophys. 
Acta-Bioenerg. 2015, 1847 (10), 1075–1084. 
(4)  Liu, X.; Kim, C. N.; Yang, J.; Jemmerson, R.; Wang, X. Cell 1996, 86 (1), 147–
157. 
(5)  Goshorn, S. C.; Retzel, E.; Jemmerson, R. J. Biol. Chem. 1991, 266 (4), 2134–2142. 
(6)  Godoy, L. C.; Muñoz-Pinedo, C.; Castro, L.; Cardaci, S.; Schonhoff, C. M.; King, 
M.; Tórtora, V.; Marín, M.; Miao, Q.; Jiang, J. F.; Kapralov, A.; Jemmerson, R.; 
Silkstone, G. G.; Patel, J. N.; Evans, J. E.; Wilson, M. T.; Green, D. R.; Kagan, V. 
E.; Radi, R.; Mannick, J. B. Proc. Natl. Acad. Sci. 2009, 106 (8), 2653–2658. 
(7)  Ott, M.; Robertson, J. D.; Gogvadze, V.; Zhivotovsky, B.; Orrenius, S. Proc. Natl. 
Acad. Sci. 2002, 99 (3), 1259–1263. 
(8)  Kagan, V. E.; Tyurin, V. A.; Jiang, J.; Tyurina, Y. Y.; Ritov, V. B.; Amoscato, A. 
A.; Osipov, A. N.; Belikova, N. A.; Kapralov, A. A.; Kini, V.; Vlasova, I. I.; Zhao, 
Q.; Zou, M.; Di, P.; Svistunenko, D. A.; Kurnikov, I. V.; Borisenko, G. G. Nat. 
Chem. Biol. 2005, 1 (4), 223–232. 
(9)  Kagan, V. E.; Bayır, H. A.; Belikova, N. A.; Kapralov, O.; Tyurina, Y. Y.; Tyurin, 
V. A.; Jiang, J.; Stoyanovsky, D. A.; Wipf, P.; Kochanek, P. M.; Greenberger, J. S.; 
Pitt, B.; Shvedova, A. A.; Borisenko, G. Free Radic. Biol. Med. 2009, 46 (11), 
1439–1453. 
(10)  Santucci, R.; Sinibaldi, F.; Cozza, P.; Polticelli, F.; Fiorucci, L. Int. J. Biol. 
Macromol. 2019, 136, 1237–1246. 
(11)  Díaz-Quintana, A.; Pérez-Mejías, G.; Guerra-Castellano, A.; De la Rosa, M. A.; 
Díaz-Moreno, I. Oxid. Med. Cell. Longev. 2020, 2020, 6813405. 
(12)  Alvarez-Paggi, D.; Hannibal, L.; Castro, M. A.; Oviedo-Rouco, S.; Demicheli, V.; 
Tórtora, V.; Tomasina, F.; Radi, R.; Murgida, D. H. Chem. Rev. 2017, 117 (21), 
13382–13460. 
(13)  Hanske, J.; Toffey, J. R.; Morenz, A. M.; Bonilla, A. J.; Schiavoni, K. H.; Pletneva, 
E. V. Proc. Natl. Acad. Sci. 2012, 109 (1), 125–130. 
(14)  Oellerich, S.; Lecomte, S.; Paternostre, M.; Heimburg, T.; Hildebrandt, P. J. Phys. 
Chem. B 2004, 108 (12), 3871–3878. 
 
166 
 
(15)  Sinibaldi, F.; Howes, B. D.; Piro, M. C.; Polticelli, F.; Bombelli, C.; Ferri, T.; 
Coletta, M.; Smulevich, G.; Santucci, R. JBIC J. Biol. Inorg. Chem. 2010, 15 (5), 
689–700. 
(16)  Milazzo, L.; Tognaccini, L.; Howes, B. D.; Sinibaldi, F.; Piro, M. C.; Fittipaldi, M.; 
Baratto, M. C.; Pogni, R.; Santucci, R.; Smulevich, G. Biochemistry 2017, 56 (13), 
1887–1898. 
(17)  Simon, M.; Metzinger-Le Meuth, V.; Chevance, S.; Delalande, O.; Bondon, A. J. 
Biol. Inorg. Chem. 2013, 18 (1), 27–38. 
(18)  O’Brien, E. S.; Nucci, N. V.; Fuglestad, B.; Tommos, C.; Wand, A. J. J. Biol. Chem. 
2015, 290 (52), 30879–30887. 
(19)  Konermann, L.; Pan, J.; Liu, Y.-H. Chem. Soc. Rev. 2011, 40 (3), 1224–1234. 
(20)  Barayeu, U.; Lange, M.; Méndez, L.; Arnhold, J.; Shadyro, O. I.; Fedorova, M.; 
Flemmig, J. J. Biol. Chem. 2019, 294 (6), 1816–1830. 
(21)  Johnson, D. T.; Di Stefano, L. H.; Jones, L. M. J. Biol. Chem. 2019, 294 (32), 
11969–11979. 
(22)  Xu, G.; Chance, M. R. Chem. Rev. 2007, 107 (8), 3514–3543. 
(23)  Møller, I. M.; Rogowska-Wrzesinska, A.; Rao, R. S. P. J. Proteomics 2011, 74 (11), 
2228–2242. 
(24)  Winkler, J. R.; Gray, H. B. Q. Rev. Biophys. 2015, 48 (04), 411–420. 
(25)  Gray, H. B.; Winkler, J. R. Proc. Natl. Acad. Sci. 2015, 112 (35), 10920–10925. 
(26)  Weisz, D. A.; Gross, M. L.; Pakrasi, H. B. Sci. Adv. 2017, 3 (11), eaao3013. 
(27)  Kathiresan, M.; English, A. M. Chem. Sci. 2017, 8 (2), 1152–1162. 
(28)  Kathiresan, M.; English, A. M. J. Am. Chem. Soc. 2018, 140 (38), 12033–12039. 
(29)  Hambly, D. M.; Gross, M. L. J. Am. Soc. Mass Spectrom. 2005, 16 (12), 2057–
2063. 
(30)  Hambly, D.; Gross, M. Int. J. Mass Spectrom. 2007, 259 (1–3), 124–129. 
(31)  Vahidi, S.; Stocks, B. B.; Liaghati-Mobarhan, Y.; Konermann, L. Anal. Chem. 2013, 
85 (18), 8618–8625. 
(32)  Vahidi, S.; Konermann, L. J. Am. Soc. Mass Spectrom. 2016, 27 (7), 1156–1164. 
  
 
167 
 
Appendix I – Permissions 
 
 
 
 
168 
 
Lysine carbonylation is a previously unrecognized contributor to 
peroxidase activation of cytochrome c by chloramine-T 
 
V. Yin, S. H. Mian and L. Konermann, Chem. Sci., 2019, 10, 2349 
DOI: 10.1039/C8SC03624A 
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 
Unported Licence. Material from this article can be used in other publications 
provided that the correct acknowledgement is given with the reproduced material and 
it is not used for commercial purposes. 
Reproduced material should be attributed as follows: 
• For reproduction of material from NJC: 
[Original citation] - Published by The Royal Society of Chemistry (RSC) on 
behalf of the Centre National de la Recherche Scientifique (CNRS) and the RSC. 
• For reproduction of material from PCCP: 
[Original citation] - Published by the PCCP Owner Societies. 
• For reproduction of material from PPS: 
[Original citation] - Published by The Royal Society of Chemistry (RSC) on 
behalf of the European Society for Photobiology, the European Photochemistry 
Association, and RSC. 
• For reproduction of material from all other RSC journals: 
[Original citation] - Published by The Royal Society of Chemistry. 
Information about reproducing material from RSC articles with different licences is 
available on our Permission Requests page. 
  
 
169 
 
 
 
 
  
 
170 
 
Curriculum Vitae 
1. NAME:  Victor Yin        
 
  
 
 
2. EDUCATION: 
 
Degree  University   Department  Year 
Ph. D.  University of Western Ontario Chemistry  Current 
B. Sc. Hon. University of British Columbia Chemistry  2015 
 
 
3. TA and OTHER RESEARCH or TEACHING RELATED EMPLOYMENT HISTORY: 
 
Date Position Course             Supervisor Department and Institution 
2017 TA  CHEM3370B    K. Baines Chemistry, UWO 
2017 TA  CHEM1302A    J. Mathers Chemistry, UWO 
2016 TA  CHEM3370B    K. Baines Chemistry, UWO 
2016 TA  CHEM1302A    J. Mathers Chemistry, UWO 
2015 TA  CHEM3391B    M. Suchy Chemistry, UWO 
2015 TA  CHEM1302A    J. Mathers Chemistry, UWO 
 
 
4. HONORS AND AWARDS: 
 
CSC 2004 UWO Student Travel Award, 2018 - $900 
CSMS Student Travel Award to ASMS, 2018 - $2000 
Lefevre Medal and Prize in Honours Chemistry (UBC), 2015 - $500 
Undergraduate Summer Research Award (UBC), 2014 - $5740 
 
 
5. SCHOLARSHIPS RECEIVED: 
 
             Scholarship type and Organization Years awarded  Amount awarded 
Alexander Graham Bell CGS-D (NSERC) 2  $35000/yr 
Queen Elizabeth II GSST 2019   1  $15000 (Declined) 
Queen Elizabeth II GSST 2018   1  $15000 
Ontario Graduate Scholarship 2016,2017 2  $15000/yr 
 
 
6. COURSES TAKEN: 
 
 Date Course Number and Title    Instructor Grade 
2018 CHEM9494B (Biophysical Chemistry) L. Konermann 99 
2016 CHEM9544A (Mass Spectrometry) L. Konermann 97 
2015 CHEM9522A (Analytical Separations) K. Yeung 90 
 
 
  
 
171 
 
7. PUBLICATIONS:  
 
Sever, A.; Yin, V.; Konermann, L. Interrogating the Quaternary Structure of Noncanonical 
Hemoglobin Complexes by Electrospray Mass Spectrometry and Collision-Induced 
Dissociation. Submitted. 
 
Yin, V.; Holzscherer, D.; Konermann, L. Delineating Heme-Mediated versus Direct 
Protein Oxidation in Peroxidase-Activated Cytochrome c by Top-Down Mass 
Spectrometry. Submitted. 
 
Yin, V.; Konermann, L. (2020) Probing the Effects of Heterogeneous Oxidative 
Modifications on the Stability of Cytochrome c in Solution and in the Gas Phase. J. Am. 
Soc. Mass Spectrom., In Press. doi: 10.1021/jasms.0c00089. 
 
Yin, V.; Mian, S. H.; Konermann, L., Lysine Carbonylation is a Previously Unrecognized 
Contributor to Peroxidase Activation of Cytochrome c by Chloramine-T. Chem. Sci., 
2019, 10, 2349-2359. 
 
Yin, V.; Shaw, G. S.; Konermann, L., Cytochrome c as a Peroxidase: Activation of the 
Pre-Catalytic Native State by H2O2-Induced Covalent Modifications. J. Am. Chem. Soc., 
2017, 139, 15701-15709. 
 
McGregor, N.; Yin, V.; Tung, C.-C.; Van Petegem, F.; Brumer, H., Crystallographic insight 
into the evolutionary origins of xyloglucan endo-transglycosylases and endo-hydrolases. 
Plant J., 2017, 89, 651-670. Featured Article. 
 
McGregor, N.; Morar, M.; Fenger, T. H.; Stogios, P.; Lenfant, N.; Yin, V.; Xu, X.; 
Evdokimova, E.; Cui, H.; Henrissat, B.; Savchenko, A.; Brumer, H., Structure-function 
analysis of a mixed-linkage Beta-glucanase/xyloglucanase from key ruminal 
Bacteroidetes Prevotella bryantii B14. J. Biol. Chem., 2015, 291, 1175-1197. 
 
 
8. SELECTED PRESENTATIONS: 
 
Yin, V*, Holzscherer, D., and Konermann, L. (2019) Delineating Heme-Mediated vs. 
Direct Protein Oxidation Pathways: Cytochrome c as a Model System. 32nd Annual Lake 
Louise Tandem Mass Spectrometry Workshop. International Conference, Poster 
Presentation. 
 
Yin, V* and Konermann, L. (2019) Cytochrome c / Cardiolipin Interactions in Apoptosis: 
The Roles of Protein Auto-Oxidation and In Situ Covalent Modifications. 67th Annual 
conference of the American Society of Mass Spectrometry. International Conference, 
Poster Presentation. 
 
Yin, V* and Konermann, L. (2018) Top-down CID-IM-MS Reveals Lysine Carbonylation 
as a Hidden Activator in the Apoptotic Peroxidase Activity of Met-Oxidized Cytochrome c. 
31st Annual Lake Louise Tandem Mass Spectrometry Workshop. International 
Conference, Poster Presentation. 
 
Yin, V* and Konermann, L. (2017) Relationship Between Oxidative Modifications and 
Peroxidase Activity of Cytochrome c: A Combined Bottom-up and Top-down 
Investigation. 30th Annual Lake Louise Tandem Mass Spectrometry Workshop. 
International Conference, Poster Presentation. 
  
 
172 
 
Yin, V*, Shaw, G., Konermann, L. (2017) Cytochrome c As A Peroxidase: Covalent 
Labeling and Oxidation Site Mapping Uncovers the Mechanism of Catalytic Activation by 
H2O2. 65th Annual Conference of the American Society of Mass Spectrometry. 
International Conference, Poster Presentation. 
 
Yin, V* and Konermann, L. (2016) Investigating the Effects of In situ Oxidation on the 
Structure and Non-Canonical Functions of Cytochrome c using Electrospray Mass 
Spectrometry. 29th Annual Lake Louise Tandem Mass Spectrometry Workshop. 
International Conference, Poster Presentation. 
 
Yin, V* and Konermann, L. (2016) Exploring the Peroxidase Activation and Deactivation 
of Cytochrome c by Heme-catalyzed Oxidative Labeling and ESI-MS. 64th Annual 
Conference of the American Society of Mass Spectrometry. International Conference, 
Poster Presentation. 
 
Yin, V*., McGregor, N., and Brumer, H. (2015) Inhibition of a plant glycoside hydrolase 
using xyloglucan-derived affinity labels. 29th Annual Western Canadian Undergraduate 
Chemistry Conference. National Conference, Oral Presentation (Undergraduate Work) 
